





MICROBES AND TOLL-LIKE RECEPTORS IN 
ORAL LICHENOID DISEASE AND ORAL 








Doctoral dissertation, to be presented for public discussion with the permission 
of the Faculty of Medicine of the University of Helsinki, in Auditorium 1, 




Department of Bacteriology and Immunology 
Haartman Institute 
Faculty of Medicine 




SUPERVISED BY:     
Riina Richardson   
DDS, PhD, FRCPath, FECMM, PGCertMedEd 
Division of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and 
Health, University of Manchester; AND Department of Infectious Diseases, Manchester 
University Foundation Trust, Wythenshawe Hospital, UK 
 
Emilia Marttila 
MD, DDS, PhD 
Department of Oral and Maxillofacial Diseases, Helsinki University Hospital and University of 
Helsinki, Finland 
 
REVIEWED BY:  
Sohvi Hörkkö 
MD, PhD, eMBA, Professor in Immunology 
Unit of Biomedicine, University of Oulu, Finland 
 
Joonas H. Kauppila 
MD, PhD, Docent 
Upper Gastrointestinal Research, Department of Molecular Medicine and Surgery, Karolinska 




Biocenter Oulu; AND Cancer and Translational Medicine Research Unit, University of Oulu, 
Finland 
 
CUSTOS:     
Tuula Salo  
DDS, PhD, Professor of Oral Pathology 
Department of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University 
Hospital, Helsinki; AND Cancer and Translational Medicine Research Unit, University of Oulu, 






Cover by Peter Rusanen 
ISBN 978-951-51-5856-7 (paperback) 










1 ORIGINAL PUBLICATIONS .................................................................................................. 5 
2 ABBREVIATIONS .................................................................................................................... 6 
3 ABSTRACT ................................................................................................................................. 8 
4 REVIEW OF THE LITERATURE ...................................................................................... 10 
4.1 Oral mucosa ................................................................................................................... 10 
4.2 Human oral microbiome ........................................................................................... 11 
4.2.1 Bacteria ................................................................................................................... 11 
4.2.2 Fungi ........................................................................................................................ 12 
4.2.3 Viruses .................................................................................................................... 13 
4.2.4 Energy metabolism of the oral microbes .................................................. 13 
4.2.5 Acetaldehyde ........................................................................................................ 14 
4.2.6 Sampling and culture of oral microbes ...................................................... 15 
4.3 Oral mucosal immune responses .......................................................................... 16 
4.3.1 Toll-like receptors .............................................................................................. 17 
4.3.1.1 Structure and localization of TLRs ...................................................... 18 
4.3.1.2 TLR ligands ................................................................................................... 18 
4.3.1.3 TLR signalling .............................................................................................. 20 
4.3.1.4 Transcription factors ................................................................................ 20 
4.4 Oral lichenoid disease ................................................................................................ 22 
4.4.1 Oral lichen planus ............................................................................................... 22 
4.4.2 Oral lichenoid lesion .......................................................................................... 24 
4.4.3 Malignant transformation ............................................................................... 25 
4.4.4 TLR and NF-κB in OLD ...................................................................................... 25 
4.5 Oral squamous cell carcinoma ..................................................................................... 27 
4.4.5 Risk factors ............................................................................................................ 27 
4.4.6 Bacteria and yeasts on OSCC lesion ............................................................. 28 
4.4.7 Treatment .............................................................................................................. 29 
5 AIMS OF THE STUDY .......................................................................................................... 31 
6 MATERIALS AND METHODS ........................................................................................... 32 
 4 
 
6.1 Materials ......................................................................................................................... 32 
6.1.1 Subjects and study design (I-IV) ................................................................... 32 
6.2 Methods ........................................................................................................................... 36 
6.2.1 Sampling methods (I, II and III) .................................................................... 36 
6.2.2 Collection of histopathological samples (IV) ........................................... 38 
6.2.3 Culture (I, II and III) ........................................................................................... 39 
6.2.4 Acetaldehyde analysis (III) ............................................................................. 42 
6.2.5 Immunohistochemical staining (IV) ............................................................ 42 
6.2.6 Microscopical analyses (IV) ............................................................................ 44 
6.2.7 Statistical methods ............................................................................................. 45 
6.2.8 Ethical considerations ...................................................................................... 45 
7 RESULTS ................................................................................................................................. 46 
7.1 Optimal sampling site in OSCC patients (I) ....................................................... 46 
7.2 Novel filter paper sampling method (II) ............................................................ 47 
7.3 ACH production and microbial colonization in OLD and OSCC (III) ........ 48 
7.4 TLR, NF-κB and p53 expression in OLD (IV) .................................................... 51 
8 DISCUSSION ........................................................................................................................... 56 
8.1 Methodological considerations .............................................................................. 60 
9 SUMMARY AND CONCLUSIONS ..................................................................................... 63 
10 ACKNOWLEDGEMENTNS................................................................................................. 64 




1 ORIGINAL PUBLICATIONS 
 
I. Rautemaa R, Rusanen P, Richardson M, Meurman JH. Optimal sampling site for 
mucosal candidosis in oral cancer patients is the labial sulcus. J Med Microbiol. 
2006 Oct;55(Pt 10):1447-51. 
II. Rusanen P, Siikala E, Uittamo J, Richardson M, Rautemaa R. A novel method for 
sampling the microbiota from the oral mucosa. Clin Oral Investig. 2009 
Jun;13(2):243-6. 
III. Marttila E, Uittamo J, Rusanen P, Lindqvist C, Salaspuro M, Rautemaa R. 
Acetaldehyde production and microbial colonization in oral squamous cell 
carcinoma and oral lichenoid disease. Oral Surg Oral Med Oral Pathol Oral Radiol. 
2013 Jul;116(1):61-8. 
IV. Rusanen P, Marttila E, Uittamo J, Hagstrom J, Salo T, Rautemaa-Richardson R. 
TLR1-10, NF-kappaB and p53 expression is increased in oral lichenoid disease. 
PLoS One. 2017 Jul 17;12(7):e0181361. 
 
 






ADH   Alcohol dehydrogenase 
ALDH   Aldehyde dehydrogenase enzyme 
BA   Lysed blood agar 
CFU   Colony forming unit 
CLED   Cysteine-, lactose-and electrolyte-deficient agar 
DAMP   damage-associated molecular pattern 
DNA   Deoxyribonucleic acid 
EBV   Ebstein-Barr virus  
EPS   extracellular polymeric substances 
FAA   Fastidious anaerobe agar 
HIV   Human immunodeficiency virus  
HPV   Human papillomavirus 
HSP  heat shock protein 
IL   Interleukin 
LAM   lipoarabinomannan 
LPS   Lipopolysaccharides 
mRNA  Messenger ribonucleic acid 
MALDI-TOF  matrix-assisted laser desorption/ionization-time of flight 
MyD88  adaptor protein in Toll/IL-1 receptor family signalling 
NF-κB   Nuclear factor-κB 
NV   Neomycin-vancomycin blood agar 
OLD   Oral lichenoid disease  
OLL   Oral lichenoid lesion  
OLP   Oral lichen planus  
OSCC   Oral squamous cell carcinoma 
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PAMP   pathogen-associated molecular pattern 
PAS   periodic acid-Schiff 
PCR   Polymerase chain reaction 
PRRs   Pattern recognition molecules 
RNA   Ribonucleic acid 
rs   Spearman’s Rho  
SEM  Standard error of mean 
SP   Saboraud dextrose agar 
TIR  TLR/IL-1 receptor 
TIRAP  TIR domain–containing adaptor protein 
TRAM   TRIF-related adaptor molecule 
TRIF   TIR domain–containing adapter protein inducing IFN-b 
TLR   Toll-like receptor 





Oral lichenoid disease (OLD) encompasses oral lichen planus (OLP) and oral 
lichenoid lesion (OLL), which are chronic T-cell-mediated mucocutaneus 
inflammatory disorders of unknown aetiology. Both OLP and OLL are classified as 
potentially malignant disorders. Although various antigens have been considered, 
it is not known what triggers the inflammatory response of T-cells. Suggested 
predisposing factors include stress, genetic factors, trauma, viral, fungal and 
bacterial infection. 
Oral squamous cell carcinoma (OSCC) is the most common malignant tumor in the 
oral cavity. It is a multifactorial disease with no single clearly recognizable cause. 
Chronic inflammation is one of the most important causes of OSCC. Chronic oral 
candidiasis has also been associated with oral carcinoma in several studies. It is 
still debatable whether microbial infections initiate cancer or is the preexisting 
cancer colonized by microbes secondarily.  
Acetaldehyde is the first metabolite of ethanol and it is carcinogenic. Acetaldehyde 
is also produced by microbes and poor oral hygiene increases acetaldehyde 
production. Recent studies of the oral microbial acetaldehyde production are 
mainly based on uncultured saliva samples. Saliva and mouth rinse samples are 
often used for general sampling but do not represent the microbes at a specific 
lesion or site.  
Toll-like receptors (TLRs) and nuclear factor-κB (NF-κB) signalling transduction 
pathway play important roles in the pathogenesis of several chronic inflammatory 
diseases. Tumour suppressor protein p53 regulates TLR expression.  
It was not known clearly what the optimal sampling site and method to study the 
microbial colonisation on mucosal lesions is and what impact specific microbial 
colonisation has on TLR expression. In addition, the immunohistochemical 
localisation of all TLRs in OLD was not established. Therefore, the aim of the first 
study was to investigate how the method and site of microbial sampling affect the 
discovery of Candida species on OSCC lesions. The objective of the second study 
was to develop a site-specific sampling method that would give quantitative 
results for samples from the oral mucosa.  The aim of the third study was to 
explore lesion specific microbes and their ability to produce acetaldehyde in OSCC 
and OLD patients. Furthermore, the aim of the fourth study was to investigate the 
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immunohistochemical staining and tissue localization of TLR1-10, p53 and NF- B 
in mucosal biopsies from patients with OLD. 
In the first study, four different sampling methods in oral cancer patients were 
compared for culture of yeasts. In the second study, two site-specific sampling 
methods, filter paper and swab, were compared for microbiological analyses of 
the healthy oral mucosa. The filter paper sampling method was developed for the 
second study. In the third study, microbial samples from OSCC and OLD patients 
for microbiological analyses and acetaldehyde measurement were obtained using 
the filter paper sampling method. In the fourth study, oral mucosal biopsies from 
patients with OLD and from healthy controls were analysed for the expression of 
TLR1-10, NF-κB and p53 by immunohistochemistry. 
This work has demonstrated that after cancer treatment, the incidence of Candida 
albicans was found to be increased and a shift from C. albicans to other Candida 
species was found. The optimal sampling site for Candida in these patients was 
found to be the labial sulcus. Moreover, the filter paper sampling method was 
found to be an ideal technique for obtaining quantitative data from defined areas 
of the oral mucosa. Based on the filter paper sampling method, it was detected that 
the bacterial composition on OSCC and OLD lesions differed from that of the 
healthy appearing contralateral mucosa and from healthy controls. Candida 
colonization was higher in OSCC and OLD lesions and patients with Candida 
colonization produced significantly more frequently mutagenic amounts of 
acetaldehyde. The staining intensity of several TLRs was markedly stronger 
throughout the epithelium and in the basement membrane zone of OLD samples. 
Likewise, the staining for NF-κB and p53 were more intense in OLD samples 
compared to the control samples. We did not find any correlations between the 
microbial samples and the immunostaining of TLRs. 
In conclusion, this study showed that the composition of lesional microbes differs 
on OSCC and OLD lesions compared to the healthy appearing mucosa and to the 
healthy controls. Furthermore, the composition rather than the number of 
microbes is a significant factor that influences the production of carcinogenic level 
of acetaldehyde. Our results indicate that acetaldehyde and Candida colonisation 
may have an impact on TLR4 expression that may play a role in OSCC 
pathogenesis. The role of soluble TLR forms in the basement membrane zone calls 
for further studies.  
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4 REVIEW OF THE LITERATURE 
4.1 ORAL MUCOSA 
Fig. 1. Oral mucosa consists of (1-4) epithelium and lamina propria. The layers in 
the epithelium are (1) stratum basale, (2) stratum spinosum, (3) stratum 
granulosum and (4) stratum corneum. Modified from Rusanen et al. 2017 (1). 
  
The oral mucosa is the inner side of the oral cavity and consists of stratified 
squamous epithelium and an underlying connective tissue termed lamina propria. 
The flattened keratinocytes in stratified squamous epithelium are arranged in 
layers maintaining a structural integrity and separate the body form its 
environment. The different layers of the epithelium are shown in figure 1. The 
basal cells form a proliferating layer that is attached to the basement membrane 
through hemidesmosomes. The keratinocytes of the basal cells differentiate into 
stratum spinosum and migrate superficially. In some region of the mouth the 
keratinocytes in the stratum granulosum differentiate into nonvital keratinized 
cells forming the stratum corneum.  Keratinized stratified squamous epithelium 
can be found in the hard palate, dorsum of the tongue and attached gingiva and 
non-keratinized epithelium can be found elsewhere in the oral cavity; including 
buccal, labial, and alveolar mucosa as well as the floor of the mouth. The basement 
membrane under the basal cells is a thin fibrous extracellular matrix and it 
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anchors the epithelium into the connective tissue underneath. The connective 
tissue is a loose cell rich layer that consists of a network of collagen and elastic 
fibres which are produced by the fibroblasts. It is also rich in many cells specific 
to immune, inflammatory, and vascular system, lymphatic and blood vessels, and 
nerves. (2) 
Oral mucosa forms a mechanical barrier against microbes and it serves as a first 
defence against infection. In addition, constant desquamation of oral epithelium 
also helps remove bacteria and other infectious agents that have adhered to the 
epithelial surfaces. Together with epidermal and circulating immune cells 
keratinocytes participate in the regulation of inflammatory reaction and immune 
responses. (2) 
4.2 HUMAN ORAL MICROBIOME 
The oral cavity is colonized by a set of microorganisms, including bacteria, 
archaea, fungi, and viruses and the composition of these microorganism varies 
according to the unique retention site of the oral cavity (3, 4). Approximately 280 
bacterial species have been isolated from the oral cavity in culture and the use of 
culture-independent molecular methods have identified over 700 species (5). The 
development of molecular sequencing techniques has provided extensive 
information of the microbial diversity in composition and genome content (3, 4).  
Biofilms are highly organised microbial communities embedded in a self-
produced matrix of extracellular polymeric substances (EPS) that adhere 
microbes to each other and to the surfaces and provide shelter and accumulation 
of nutrients to the microbes (6). Through the intercellular physical and social 
interaction together with the EPS the biofilm is distinct to free living microbes and 
is not predictable from the study of free-living bacterial cells  (6). The biofilm 
enables an enhanced resistance or tolerance to antibiotics and other antimicrobial 
agents compared with free-living bacterial cells (6). The composition of biofilms 
is affected by many factors like age, diet, oral hygiene, host immune responses, 
and medication and it varies with the balance between health and disease 
conditions (7). 
4.2.1 Bacteria 
Various analysis have revealed that 96% of oral bacteria in a healthy oral cavity 
constitutes of six major phyla: Actinobacteria, Proteobacteria, Firmicutes, 
Fusobacteria, Bacteroidetes and Spirochaetes (4, 8, 9).  The other major 
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constituents of the core microbiome of the oral cavity include Actinomyces, 
Atopobium, Corynebacterium, Rothia of Actinobacteria; Bergeyella, 
Capnocytophaga, Prevotella of Bacteroidetes; Granulicatella, Streptococcus, and 
Veillonella of Firmicutes; Campylobacter, Cardiobacterium, Haemophilus, Neisseria 
of Proteobacteria; Saccharibacteria, and Fusobacteria (9). The oral microbial 
composition differs in between healthy individuals and in between different 
niches in oral cavity (7). The dominant groups of bacteria in supragingival dental 
plaque are Firmicutes and Actinobacteria while anaerobic Prevotella and 
Capnocytophaga of Bacteroidetes are found in the niches of dorsal and lateral 
surfaces of tongue (4). Microbes attached to surfaces continuously shed into the 
saliva and each millilitre of saliva contains an average 1.4 x 108 colony forming 
units (CFU) bacteria from which the Streptococcus among Firmicutes is the most 
abundant bacteria (9). The composition of bacteria in saliva varies extensively and 
patients with dental periodontitis (10), caries (11) and oral squamous cell 
carcinoma (12) show a different salivary bacterial composition and distribution 
from healthy populations (7). With the development of periodontal disease, 
Porphyromonas gingivalis, Tannerella forsythia and Treponema denticola are the 
most abundant bacteria (13). Streptococcus mutans has been regarded as a specific 
pathogen in dental caries but also Streptococcus, Lactobacillus, Actinomycetes, 
Propionibacterium, and Veillonella were also detected at a higher amount in caries-
active adults (14). While the microbial composition varies in between different 
niches and sites in oral cavity, it underlines the importance of choosing a correct 
sampling strategy which strictly complies with the aim of the microbiological trial 
(15). 
4.2.2 Fungi 
Fungi comprise a minor component of the oral microbiome and for most people, 
yeasts are a part of the normal oral flora (16). Candida albicans is the most 
frequently detected fungal species in the oral cavity and other less common 
species include C. parapsilosis, C. tropicalis, C. glabrata, C. krusei, C. dubliniensis, C. 
stellanoidea and C. kefyr (17). In healthy individuals, the amount of fungi is 
controlled by specific and non-specific defence mechanisms of the saliva and the 
oral mucosa, as well as by competition among oral microbes (18). However, if the 
balance of the normal flora is disrupted or the local or systemic immune defences 
mechanism are compromised, Candida often become pathogenic, causing mucosal 
disease (19). Candida is also involved in other diseases like caries and it is highly 
associated with the severity of chronic periodontitis (7). Human infections caused 
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by Candida range from the more common oral thrush to fatal, systemic 
superinfections in patients who are afflicted with other diseases (20). Chronic oral 
candidiasis has been associated with oral carcinoma in several studies (21-23). 
Common predisposing factors that cause candidiasis are reduced saliva secretion 
due to medication or radiotherapy, primary or secondary deficiencies of humoral 
or cell mediated immunity, local mucosal diseases, and the use of wide-spectrum 
antibiotics (19). Although all Candida species cause a similar mucosal infection, 
there are remarkable differences in the antifungal susceptibilities and 
invasiveness among species (24, 25). 
4.2.3 Viruses 
Viruses are small infectious agents that require living cells of other organisms like 
in the cells of animals, plants, bacteria, and fungi for replication. All viruses contain 
the following two components: a nucleic acid genome and a protein capsid that 
covers the genome. Together this is called the nucleocapsid. In addition, many 
animal viruses contain a lipid envelope. The entire intact virus is called the virion. 
Viruses do not have a cellular structure or their own metabolism and therefore 
cannot reproduce outside a host cell (26). The oral virome contains a range of 
viruses and their presence may be closely related to oral microbial diversity (27). 
Viruses that have infected bacteria may have a substantial capacity to alter human 
bacterial communities and may have a role in both health and in disease, such as 
chronic periodontitis (27, 28).  
Viruses have extensive effects on the host cell. Most viral infections eventually 
cause death to the host cell through different mechanisms, such as cell lysis, 
alterations to the cell's surface membrane, or apoptosis. Some viruses can stay 
latent and inactive causing no apparent changes to the infected cell. Oral viruses 
are associated to diseases, such as herpes zoster (varicella zoster virus), herpetic 
gingiva-stomatitis and herpes labialis (herpes simplex virus), and papillomas 
(human papilloma virus) (29, 30). In addition, Epstein-Barr (EBV) virus can cause 
oral ulcers, multiple palatal petechia or infrequently gingival ulcerations (31). In 
active periodontal lesions different viruses can be detected, such as human 
cytomegalovirus (HCMV), EBV type 1–2, herpes simplex virus (HSV) type 1, and 
human herpes virus types 6–8 (7, 32).  
4.2.4 Energy metabolism of the oral microbes 
Bacteria, fungi and parasites uptake and utilize inorganic or organic compounds 
required for growth and maintenance of cellular steady state. To maintain their 
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basic functions and to replicate when in an appropriate milieu, these microbes 
must generate energy through substrate oxidation and dissimilation reactions. 
These reactions are catalysed within the bacterial cell by integrated enzyme 
systems. Chemical energy generated by substrate oxidations is conserved by 
formation of high-energy compounds such as adenosine diphosphate (ADP) and 
adenosine triphosphate (ATP) or compounds containing the thioester bond such 
as acetyl-CoA or succinyl-CoA (33). Bacteria, like mammalian and plant cells, use 
ATP or the high-energy phosphate bond as the primary chemical energy source to 
synthesize the new complex organic compounds needed by the cell. Bacteria 
require also B-complex and vitamins as functional coenzymes for many oxidation-
reduction reactions. For the ATP synthesis the most oxidized compounds are 
carbohydrates (particularly glucose), protein and lipids. (33) 
In bacteria, glycolysis can occur in one of several pathways by which bacteria 
dissimilate glucose. The complete oxidation of glucose may involve three 
fundamental biochemical pathways: glycolytic pathway, citric acid cycle or 
membrane-bound electron transport oxidations coupled to oxidative 
phosphorylation. Citric acid cycle is a series of chemical reactions used by all 
aerobic microbes. The glycolytic pathway is most commonly associated with 
anaerobic or fermentative metabolism in bacteria and yeasts. In aerobic 
respiration the molecular O2 serve as terminal acceptor of electrons and in 
anaerobic respiration, NO3–, SO42–, CO2, or fumarate can serve as terminal electron 
acceptors. The result of the respiratory process is the complete oxidation of 
carbohydrate into CO2 and H2O. (33, 34) 
In fermentation, energy is generated in anaerobic condition through the 
dehydrogenation reactions that occur as glucose is broken down enzymatically. 
For most microbial fermentations, glucose dissimilation occurs through the 
glycolytic pathway and the organic compound most commonly generated is 
pyruvate or a compound derived enzymatically from pyruvate, such as 
acetaldehyde and acetyl-CoA. Acetaldehyde can then be reduced by nicotinamide 
adenine dinucleotide (NADH + H+) to ethanol, which is excreted by the cell. (33, 
34) 
4.2.5 Acetaldehyde 
Acetaldehyde is the first metabolite of ethanol and this reaction is catalysed by 
alcohol dehydrogenases (ADH). Many bacteria possess marked ADH activity and 
alcohol-derived acetaldehyde exposure may occur in the oral cavity 
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independently from liver metabolism (35). Several studies performed in humans 
found higher levels of acetaldehyde in saliva compared to those found in blood 
after alcohol consumption (36-39). Acetaldehyde is reactive and toxic and has 
been classified by the International Agency for Research on Cancer (IARC) as a 
group 1 carcinogen (40, 41). The carcinogenic concentration of aldehyde as low as 
100μM can be measured in saliva after moderate alcohol consumption (39-42). 
Acetaldehyde interferes with DNA synthesis and repair at many sites and these 
alterations may result in tumour development (36, 38, 39). Acetaldehyde also 
induces inflammation and metaplasia of the tracheal epithelium and enhances cell 
injury (38). While cellular ADHs represent an important source of acetaldehyde, 
it can also be formed in the human oral cavity by the action of microorganisms 
such as oral Streptococci, Neisseria spp. and Candida (42-46). Thus, poor oral 
hygiene increases acetaldehyde production into saliva (43). Acetaldehyde can also 
be found in tobacco smoke. For oral squamous cell carcinoma (OSCC), smoking 
and poor oral hygiene are risk factors that amplify the malignant effects of 
simultaneous alcohol consumption (42, 47, 48).  
Recent studies of the oral microbial acetaldehyde production are mainly based on 
uncultured saliva samples (36, 42, 43, 45). Saliva and mouth rinse samples are 
often used for general sampling but do not represent the acetaldehyde producing 
microbes at a specific lesion or site.  
4.2.6 Sampling and culture of oral microbes 
The oral cavity includes several distinct sites, such as teeth, tongue, lip, cheek, 
gingival sulcus, attached gingiva, hard palate, and soft palate which are colonized 
by distinct microbes (5). In health, there is a balance between oral 
microorganisms and the local defensive mechanisms and changes that alter that 
balance may lead to disease. Factors that may alter this balance include changes 
in the integrity of the epithelium, changes in secretion of saliva or in the immune 
system (5). Oral microorganisms may be the primary cause of oral lesions or 
secondary invaders in an already established mucosal lesion (49).  
The oral microflora has been shown to differ both in spectrum and quantity in 
healthy mucosa compared to, for example, oral cancer lesions (44, 47, 50, 51), 
aphthous ulcers (52), and chronic mucosal oral diseases (49). Samples for 
microbiological analysis should be collected from a site representative of the 
active disease process (8). A sterile swab is the most commonly used method for 
sampling a mucosal lesion (5). However, although swab samples can detect 
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microbes on a certain area, it is still a quantitative estimate and the technique is 
difficult to standardize. Mouth rinse and saliva samples are often used for general 
sampling, but these methods cannot identify the site of infection and may miss 
adherent species (53). In addition, mouth rinse and saliva samples may not be 
useful for patients lacking tongue or lip function or for patients with lowered 
saliva secretion, for example, due to the radical changes during treatment for oral 
cancer (51, 53).  
For microbial culture, the sample is plated onto non-selective and selective media. 
The non-selective media support the growth of many oral species and the selective 
media is used to help to identify specific species. The culture plates are incubated 
under appropriate atmospheric conditions up to 7 days after which different 
colonies can be detected and analysed. Microbes are identified using Gram 
staining, microscopy, and biochemical tests (54). In recent years matrix-assisted 
laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry has 
been demonstrated as a fast and cost-effective identification method in clinical 
microbiology laboratories (55-57). The identification of cultured bacteria or 
yeasts by MALDI-TOF mass spectrometry is based on ionization technique where 
the mass spectrum of an ionizing molecule is measured by a detector. 
4.3 ORAL MUCOSAL IMMUNE RESPONSES 
The oral cavity is constantly protected from invading microbes, foreign antigens, 
and toxic agents by non-specific and specific immune mechanisms. Oral mucosa 
serves as a barrier against the invading microbes and several defence mechanisms 
of the saliva, as well as the competition among oral microbes, constantly reduces 
the number of oral microbes. In health, the immune system recognizes and 
removes the invading pathogens and can distinguish the body's own cells from 
invading pathogens and infected cells. (5)  
The human immune system can be divided into innate and adaptive immunity. In 
the adaptive immunity the T and B lymphocytes play a major role. B lymphocyte 
activation begins when it binds to an antigen after which it differentiates into an 
antibody secreting plasma cell. T lymphocytes are mobilized when they encounter 
an antigen presenting cell (APC) such as dendritic cell, B lymphocyte or 
macrophages. Other cell types such as keratinocytes can also present an antigen. 
Depending on the T lymphocyte subgroup activated they can regulate immune 
responses, or they can directly attack infected or cancerous cells carrying foreign 
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peptides on their surfaces. T lymphocyte subgroups include helper, killer, 
regulatory, and potentially other T-cell types, such as auto-cytotoxic CD8+ T-cells.  
The adaptive immune system develops slowly but it is highly specific to a certain 
pathogen and it can also provide long-lasting protection. In contrast, the innate 
immune system does not have an immunological memory but once activated by 
foreign invaders the innate immune system provides an immediate response. The 
innate immune system includes e.g. cytokines, serum complement and broadly 
distributed phagocytic cells and leucocytes that recognises pathogen through 
pattern recognition receptors (PPRs). (58, 59) 
If a pathogen invades the oral mucosa, an inflammatory reaction develops, and the 
immune system aims to destroy the invader. Some microbes can evade the 
immune system and cause a chronic infection despite the concerted activity of the 
immune mechanism. In fact, many inflammatory conditions and immunological 
disorders have been linked to a specific microorganism (60, 61). The role of 
chronic inflammation and the innate immune system in the development of cancer 
is widely recognized and a strong link between chronic inflammation and many 
types of cancers have been reported (62). 
4.3.1 Toll-like receptors 
Toll-like receptors (TLRs) are receptors of the innate immunity. They are 
expressed on various immune cells, such as macrophages and dendritic cells but 
are also present in non-immune cells, such as keratinocytes of the skin and oral 
mucosa (63). TLRs belong to the pattern recognition receptors (PRRs) which 
recognize molecules of pathogens known as pathogen-associated molecular 
patterns (PAMPs) and trigger the release of inflammatory cytokines and type I 
interferons for host defence  (63). The responses of the TLRs are important not 
only to eliminate pathogens but also to develop the pathogen-specific adaptive 
immunity, which is mediated by B- and T-cells (64). TLRs also maintain tissue 
homeostasis by regulating the inflammatory and tissue repair responses to injury 
(65).  
TLRs regulate a wide range of biological responses including inflammatory and 
immune responses during carcinogenesis (66). TLRs may promote carcinogenesis 
through proinflammatory, anti-apoptotic, proliferative and profibrogenic signals 
in either the tumour microenvironment or tumour cells themselves (66). One 
important tumour-promoting signalling pathway induced by TLR signalling is the 
transcription factor NF-κB, as described below. Association of TLRs with the risk 
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of oral squamous cell carcinoma (OSCC) is still conflicting and the available 
evidence is weak due to the sparseness of data or disagreements among the 
reported investigations (67). However, high expression of TLR4 was significantly 
associated with the outcome of patients with solid cancers (68). 
4.3.1.1 Structure and localization of TLRs 
TLRs are transmembrane receptors with a leucine rich extracellular domain that 
are involved in the ligand recognition. The intracellular domain is known as 
TLR/IL-1 receptor (TIR) domain which is analogous to that of interleukin 
receptors and is essential for signal transduction (69). In human, so far, ten TLRs 
have been identified of which TLR1,2,4,5,6 are expressed on the cell surface and 
TLR3,7,8,9 are expressed on intracellular vesicles, such as the endosome (63). The 
cellular localization of TLR10 has not yet been well characterized but according to 
Lee et all 2018, TLR10 could be detected on the cell surface but was more 
abundant intracellularly (70). The cellular localization of TLRs correlates with 
their functions in sensing invading pathogens (70). Soluble forms of several TLRs 
have been detected in body fluids, such as breast milk, plasma and saliva (71-74). 
TLRs recognize various PAMPs derived from viruses, bacteria and fungi and 
protozoa (63). The ligand diversity is further broadened by forming heterodimers, 
such as TLR1/2 or TLR2/6 and TLR4/MD-2 (63, 75). TLR1-10 localization, ligands 
and signalling are presented in figure 2.  
4.3.1.2 TLR ligands 
Representative PAMPs of bacterial cell wall components are recognized by 
different TLRs: Lipopolysaccharides (LPS) of gram-negative bacteria are 
recognized by TLR4; peptidoglycans and several lipoproteins from gram-positive 
and gram-negative bacteria or lipoarabinomannan (LAM) from mycobacteria are 
recognized by TLR2; diacyl or triacyl lipopeptides from bacteria, mycobacteria, 
and mycoplasma are recognized by TLR1/2 or TLR2/6 (76). Although, 
Mycoplasma does not possess cell walls, its plasma membrane also contains 
several lipopeptides which are recognized by TLR2, TLR2/1 or TLR2/6 (76). TLRs 
can also recognize proteins, such as flagellin from flagellated bacteria (TLR5). 
Viruses are important PAMPs which contain envelope proteins and nucleic acids 
(single stranded (ss) or double stranded (ds) RNA or ss/ds DNA) and are 
recognized by various TLRs. Envelope proteins from viruses are recognized by 
TLR2, TLR4, and TLR6 and virus derived nucleic acids are recognized by TLR3 
(dsRNA), TLR7 and TLR8 (ssRNA) and TLR9 (DNA)(77, 78). Several components 
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of Candida spp. such as β-glucan, chitin, mannan, proteins, and nucleic acids are 
recognized by at least five TLRs (TLR2, TLR4, TLR6, TLR7, and TLR9)(77). The  
cell surface located TLR2 and TLR4 play crucial roles in the recognition of the 
Candida spp. whereas, intracellularly located TLR7 and TLR9 participate in the 
recognition of the fungal nucleic acids that are released into TLR-containing 
vesicles during the digestion by phagocytes (77, 79).   
In addition to the exogenous PAMPs, TLRs can be activated also by endogenous 
signals, such as damage-associated molecular patterns (DAMPs) released from 
dead and dying cells (80). The presence of DNA or RNA anywhere other than the 
nucleus or mitochondria is perceived as a DAMP and are censed by intracellular 
TLRs. Inappropriate TLR signalling stimulated by extrinsic PAMPs and self-
DAMPs holds the potential to activate uncontrolled activation of self-reactive B- 
and T-cells which induce autoimmunity assisted by the cells of the innate 
immunity (80). 
 
 Fig. 2. TLR1-10, ligands and signalling pathways (63, 70). Modified from Kumar 





4.3.1.3 TLR signalling 
The engagement of TLRs by microbial components triggers the activation of signal 
cascades, leading to specific immunological responses (77). After ligand binding, 
the intracellular TIR-domain binds to a single, or to a specific combination of 
recruited adaptor molecules, such as MyD88, TIRAP, TRIF and TRAM (77). All 
TLRs except TLR3 recruits MyD88 which leads to the activation of NF-κB and 
mitogen-activated protein (MAP) kinase and the induction of inflammatory 
cytokines (76). TLR3 and TLR4 (with the combination with TRAM) use TRIF to 
activate an alternative pathway leading to the activation of NF-κB and IRF3 and 
the induction of type I interferons and inflammatory cytokine productions (77). 
TLR2 and TLR6 use also TIRAP as an additional adaptor molecule in addition to 
MyD88. Because of the complexity of the signal cascade, the TLR signalling 
pathway is categorized into MyD88-dependent and TRIF dependent pathways 
(76, 77). The ligand diversity of TLRs can be explained in part by the selective 
usage of these adaptor molecules (77). Stimulation of several TLRs leads to the 
activation of several transcription factors, such as NF-κB and to the induction of a 
variety of genes for cytokines, chemokines, and co-stimulatory molecules which 
play essential roles in recruiting various inflammatory cells into the infection sites 
and activating the adaptive immune response later in infection (77). 
4.3.1.4 Transcription factors 
4.3.1.4.1 NF-κB 
Nuclear factor-κB (NF-κB) acts as a central mediator of immune and inflammatory 
responses. It is also involved in stress responses and regulation of cell 
proliferation and apoptosis (81). NF-κB are present in cells in an inactive state and 
after activation and nuclear translocation it controls the expression of genes 
encoding immune and pro-inflammatory mediators, such as TNF-α, IL-1β and 
leukocyte and vascular adhesion molecules, which further propagate and amplify 
the inflammatory response (82). Some of these pro-inflammatory mediators can 
also activate NF-κB and this type of positive regulatory loop may exacerbate and 
perpetuate local inflammatory reactions (83). Based on the significance with 
innate and adaptive immunity and cellular processes such as cell survival, 
proliferation, migration, and invasion the NF-κB activity is tightly regulated (62). 
Dysregulation at any stage in the NF-κB activation pathways may result in chronic 
inflammation, autoimmunity, and cancer (62, 83). NF-κB activation and 
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inflammatory cytokines has been demonstrated to play an important role also in 
oral lichen planus (OLP) (84). 
The significance of NF-κB activity in cancer is further supported by several 
previous studies indicating a functional link between NF-κB and the tumour 
suppressor protein, p53 (85, 86). Since NF-κB is predominantly activated by 
extrinsic stresses, such as presence of bacteria and viruses, p53 acts as a guardian 
against intrinsic stresses, such as DNA damage and deregulation of 
protooncogenes (87). The p53 and NF-κB pathways negatively regulate each other 
and are deregulated in opposite directions in tumours (85, 86). This antagonistic 
relationship of these transcription factors reflects the opposite principles of the 
physiological responses against intrinsic and extrinsic cell stresses (85). 
4.3.1.4.2 p53 
The tumour suppressor protein p53 is a transcription factor that plays an 
important role in preserving the genomic integrity; it controls the cell cycle and 
apoptosis if the DNA damage cannot be repaired (62). p53 may also influence 
immune responses by regulating TLR expression and the response of TLRs to their 
ligands (88, 89). Under normal conditions p53 resides in the cytoplasm in an 
inactive form and in response to various cellular stresses, such as DNA damage, 
virus infection, oxidative stress, and oncogene activation, it translocates into the 
nucleus (90). In the nucleus, p53 binds to several specific DNA sites and regulate 
transcription of numerous responsive genes and allows the cell to respond 
adequately to the applied stress (85). Physiologically, p53 prevents damaged cells 
from proliferating which is important because damaged cells are more likely to 
contain mutations which could lead to the development of cancer (90). A healthy 
cell maintains p53 at low levels and its half-life is short while the inactive and 
mutated p53 remains for longer periods in the cell and leads to cellular damage 
(91). The p53 protein is the most frequently mutated tumour suppressor in cancer 
and mutations of the TP53 gene can be found in approximately half of all human 
tumours (90). This may indicate that p53 plays a crucial role in preventing 
malignant transformation (90). In turn, overexpression of p53 has been 




4.4 ORAL LICHENOID DISEASE 
Oral lichenoid disease (OLD) encompasses oral lichen planus (OLP) and oral 
lichenoid lesion (OLL) which are chronic mucocutaneus inflammatory disorders 
of unknown aetiology (92, 93). Also, the term oral lichenoid reaction (OLR) is used 
for lesions that are like OLP. However, both OLL and OLR lack some of the clinical 
and/or histopathological features of OLP (94). The majority of OLP and OLL 
patients report a burning sensation or pain when eating or swallowing hot or spicy 
food that affects their quality of life (95). Most cases of symptomatic OLP are 
associated with erythematous and ulcerative lesions (96). Since there is no 
curative treatment for OLP the aim of current therapy is to eliminate mucosal 
erythema and ulcerations and alleviate symptoms (95).  The improvement and 
control of oral hygiene should be a primary consideration in the management of 
OLP (97). In addition, mechanical trauma caused by badly fitting dentures or 
sharp filling margins or rough surfaces of dental restorations should receive 
attention (95).  
Topical corticosteroids are used most commonly for the treatment of OLP. Topical 
cyclosporine, topical tacrolimus, or systemic corticosteroids may be indicated in 
patients whose condition is unresponsive to topical corticosteroids (98). The most 
important complication in OLP and OLL patients is the malignant transformation 
of the lesion even though the exact mechanism has not been clarified (99). 
However, regular follow-up for these patients is recommended (100).  
4.4.1 Oral lichen planus 
The prevalence of OLP is 0.5–4% depending on the population studied. It affects 
women more commonly than men and occurs mostly between 30 and 60 years of 
age (101). OLP is most commonly involved on the buccal mucosa (up to 90%), 
gingiva, dorsum of the tongue, labial mucosa, and lower lip (102). The clinical 
criteria for OLP issued by the World Health Organisation (WHO), indicates that 
OLP presents with multiple lesions in a bilateral and roughly symmetric 
distribution with presence of slightly raised grey-white lines (103)(Table 1). OLP 
has a wide range of clinical appearances that correlate with disease severity; 
reticular, erosive and, plaque-like are the most common ones and the ulcerative 
and bullous types are less common (104, 105). 
The histology of OLP is characterized by the presence of a bandlike subepithelial 
infiltrate of inflammatory cells, predominantly T-lymphocytes within the 
epithelium and adjacent to damaged basal keratinocytes (93). In addition, the OLP 
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lesion shows degeneration of basal cells, disruption of the anchoring elements 
(hemidesmosomes, filaments and fibrils), and changes in the basement membrane 
that comprise breaks, branches, and duplications (106). Also, parakeratosis, 
acanthosis and “saw-tooth” rete peg formation are typical findings in OLP (106).  
The precise cause of OLP is unknown. However, current data suggest that OLP is a 
T-cell-mediated autoimmune disease in which cytotoxic CD8+ T-cells trigger 
apoptosis of oral epithelial cells (106). During the initial phase CD8+ T-cells may 
recognize a self-peptide antigen expressed in association with the human 
leucocyte antigen (HLA) class I histocompatibility complex on lesional 
keratinocytes making lichen planus a true autoimmune disease (106). 
Alternatively, the antigen can be presented by antigen-presenting cells (APC), 
including Langerhans cells or keratinocytes in association with HLA class II 
histocompatibility complex to CD4+ T-cells (107). In the pathogenesis of OLP, it is 
likely that antigen presentation to both CD8+ and CD4+ T-cells is required to 
generate CD8+ cytotoxic T-cell activity (107).  
An early event in lichen planus lesion formation may be keratinocyte antigen 
expression only at the future lesion site induced by different external or internal 
agents (106). This in turn, may alter the basal keratinocytes making them 
susceptible to apoptosis by cytotoxic T-cells (106). Such agents may be systemic 
drugs (lichenoid drug reaction), contact allergens in dental restorative materials 
or toothpastes (contact hypersensitivity reaction), mechanical trauma, viral or 
bacterial infection that induces the heat shock protein (HSP) antigen expression 
presented by keratinocytes (93). Thus, keratinocyte HSP expression in OLP may 
be an epiphenomenon associated with pre-existing inflammation caused by 
microbes (107). Also, other aetiological factors believed to be associated with OLP, 





Table 1. Modified WHO diagnostic criteria of oral lichen planus (OLP) and oral 
lichenoid lesions (OLL) (103, 108).  
Clinical criteria 
 Presence of bilateral, roughly symmetrical lesions 
 Presence of reticular pattern; a lace-like network of slightly raised gray-white lines 
 In the presence of reticular lesions elsewhere in the oral mucosa, erosive, plaque-like, 
bullous, and atrophic lesions are accepted as a subtype 
 In all other lesions that resemble OLP but do not complete the above criteria, the term 
“clinically compatible with” should be used 
Histopathologic criteria 
 Band-like zone of cellular infiltration that is confined to the superficial part of the 
connective tissue, predominantly lymphocytic infiltration 
 Liquefaction degeneration of basal cell layer 
 Absence of epithelial dysplasia 
 When the histopathologic features are less obvious, the term “histopathologically 
compatible with” should be used 
Final diagnosis OLP or OLL 
 To achieve a final diagnosis both clinical and histopathologic criteria should be 
included 
OLP  A diagnosis of OLP requires fulfilment of both clinical and histopathologic criteria 
OLL  The term OLL will be used under the following conditions: 
1. Clinically typical of OLP but histopathologically only “compatible with” OLP 
2. Histopathologically typical of OLP but clinically only “compatible with” OLP 
3. Clinically “compatible with” OLP and histopathologically “compatible with” OLP 
 
4.4.2 Oral lichenoid lesion 
The oral mucosa also manifests lichenoid lesions (OLL), such as hyperkeratotic, 
white, thickened, inflammatory reactions, which are most commonly considered 
as an immunopathological reaction to various aetiological factors, such as 
systemic drug exposure and local contact hypersensitivity against dental 
restorative materials like amalgam (102, 105). Despite of the distinct 
aetiopathological features, OLP and OLL are histologically indistinguishable and 
therefore the diagnosis is based on both clinical and histological findings (104). 
Since both conditions possess overlapping clinical and histopathological features, 
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similar therapies may be used in OLP and OLL (105). However, unlike OLP, OLL 
resolves after elimination of the causative agent (105). 
4.4.3 Malignant transformation 
Both OLP and OLL are classified as potentially malignant disorders (100, 
108).  According to the latest meta-analysis the frequency of malignant 
transformation in OLP ranges from 0,5% to 1.3% and in OLL from 1,2% to 4,9%, 
respectively (109). The average time from the diagnosis to the malignant 
transformation is 51,4 months (100). In OLP the highest malignant transformation 
rate noted is in erosive lesions and the most common site of malignant 
transformation was the tongue (30%), followed by the buccal mucosa (20%) and 
gingiva (17%) (109). Malignant transformation is still controversial due to the 
lack of universally accepted specific clinical diagnostic criteria of OLP and further 
prospective studies are required (102, 110). However, it has been suggested that 
the oral mucosa affected by OLP may be compromised to the extent of being more 
sensitive to exogenous mutagens in alcohol, tobacco, and microbes (96). 
Alternatively, the chronic inflammatory response and simultaneous mucosal 
wound healing response in OLP may increase the likelihood of cancer-forming 
gene mutations (96). This hypothesis was supported by findings which showed 
that macrophage migration inhibitory factor (MIF) released from T-cells and 
macrophages suppresses the transcriptional activity of the p53 (111). Cellular 
stress, such as DNA damage, can lead to activation of p53 that play an important 
role in preserving the genomic integrity (62). An association between 
overexpression of p53 and chromosomal alterations has been shown in OLP (91).  
4.4.4 TLR and NF-κB in OLD 
As mentioned before, stimulation of several TLRs leads to the activation of several 
transcription factors, such as NF-κB and dysregulation at any stage in the NF-κB 
activation pathways may result in chronic inflammation, autoimmunity, and 
cancer (62, 112). Still the function of TLRs and NF- κB in OLP remains unclear (84, 
113). Keratinocytes in OLP lesion show an increased NF-κB activity which is 
correlated with the recruitment of numerous cytotoxic cells in OLP (84). The 
degree of NF-κB activation in OLP has been suggested to correlate with the 
severity of the disease (84). In previous literature on TLR and OLD, several TLRs 
expression, specially TLR1, TLR2, TLR4 and TLR9 were shown to be increased in 
the lesions compared to the healthy oral mucosa (114-120) (Table 2). In addition, 
 26 
 
soluble forms of TLR2 and TLR4 were found to be increased and functional in 
saliva in OLP patients (71, 73).  
 
Table 2. The expression several TLRs has been shown to be increased in OLP 
compared to the healthy oral mucosa. IHC: Immunohistochemical staining; RT-
PCR: real-time PCR; sTLR: soluble TLR; IF: immunofluorescence; WB: western 
blot; FCM: flow cytometry; ↑ and ↓: up- and downregulation; ±: no differences 
between the groups. 
TLR Disease TLR studied Sample Method Reference 












Biopsies IHC,  
RT-PCR 
(118) 
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samples, DNA was 
extracted from the 







OLR TLR1-10 Biopsies IHC,  
RT-PCR 
(119) 
TLR4↑ OLP TLR4 Biopsies and cell 
culture 
IF (125) 
TLR4↑ OLP TLR4 Cell culture RT-PCR (126) 
TLR2±, TLR3↓, 
TLR4↑, TLR8± 
OLP TLR2, TLR4, 
TLR8 












were associated with 
OLP 
OLP TLR2, TLR3, 
TLR4 
Biopsies RT-PCR (127) 
TLR2 ± OLP TLR2 Saliva and blood 
samples 
RT-PCR (128) 
TLR4↑ OLP TLR4 Biopsies IHC, 
RT-PCR 
(113) 
TLR4↑, TLR9↑ OLP TLR4, TLR9 Biopsies IHC (114) 
TLR2↓, TLR4↑ OLP TLR2, TLR4 Biopsies IHC, 
RT-PCR 
(115) 
TLR2↑, TLR4↓ OLP TLR1-10 Biopsies IHC, 
RT-PCR, FCM 
(116) 
sTLR4↑ OLP sTLR2, sTLR4 Saliva samples WB (73) 
sTLR2↑ OLP sTLR2 Saliva samples WB (71) 




4.5 ORAL SQUAMOUS CELL CARCINOMA 
Oral squamous cell carcinoma (OSCC) is the most common malignant tumor in the 
oral cavity and accounts for more than 90% of all oral cancers (129). There is 
much geographical variation regarding mortality rates and incidence which is 
increasing in many parts of the world despite all the advances in modern medicine 
(129). According to the latest reports of the International Agency for Research on 
Cancer (IARC) for oral cancer, including lips and oral cavity, annual estimates of 
age standardized incidence and mortality are 5,5/100 000 and 2,7/100 000 in 
men and 2,5/100 000 and 1,2/100 000 in women, respectively  (129). In Finland 
in 2015 there were over 410 new cancers of lip, tongue and oral cavity cancer and 
the mortality rates were over 140 in both sexes  (130). Regardless of advances in 
surgical techniques the five-year overall survival rate in Finland for OSCC of the 
tongue remains 47% (131). The mean age at diagnosis for oral cancer is 60 years 
in men and 67 years in women (132). There is substantial evidence that early 
diagnosis would reduce the morbidity and mortality from oral cancer (48). 
4.4.5 Risk factors 
Tobacco (also smokeless) and chronic alcohol consumption are the two most 
important known risk factors for the development of OSCC. They have been shown 
to have a synergic effect (133). It has been estimated that smoking causes over 
85% of deaths caused by oral cancer (134). In addition, poor oral hygiene with 
smoking and simultaneous alcohol consumption have been associated with 
increased risk of oral cancer in several studies (42, 47, 48). Other possible risk 
factors for OSCC include chronic infections, viral infections, such as HPV, 
immunodeficiency, UV radiation, dietary factors, and precancerous lesions, such 
as erytroplakia and leucoplakia (62, 135). OSCC is a multifactorial disease with no 
single clearly recognizable cause. However, it has been estimated that 75% of all 
oral cancers could be prevented by the elimination of risky lifestyles such as 
tobacco smoking and alcohol consumption and by protecting against solar 
irradiation (136).  
OSCC develops over many years and during this period epithelial cells are affected 
by various mutagens, especially alcohol and tobacco (48). Oncogenesis is a 
progression from a normal healthy cell to a pre-malignant or a potentially 
malignant cell, where several DNA mutations occur leading to loss of growth 
control and eventually the ability to proliferate autonomously (48).  One of the 
fundamental concepts of the genetic mechanisms behind cancer is the 
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overexpression of oncogenes and/or the silencing of tumour suppressor genes, 
such as p53 (90).  
4.4.6 Bacteria and yeasts on OSCC lesion 
Infection is one of the most important causes of cancer and almost one in every 
five malignancies can be attributed to infectious agents (137). Several bacterial 
species have been associated with different cancers. For example, Chlamydia 
trachomatis infection has been associated with an increased risk for the 
development of invasive cervical carcinoma (138). Bacteraemia and endocarditis 
due to Streptococcus bovis have likewise been linked with malignancies in the 
colon (139). Helicobacter pylori infection has been considered a causative agent of 
both gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphomas 
(140). The association of microbes with OSCC is of increasing interest. Emerging 
evidence suggests a link between chronic periodontal disease and oral cancer and 
variety of periodontal bacteria such as Porphyromonas gingivalis, Fusobacterium 
nucleatum, Prevotella intermedia, are related to OSCC (141). It has been 
demonstrated that surface biofilms in oral carcinoma harbour significantly 
increased numbers of aerobes and anaerobes as compared to the healthy mucosa 
surface on the same patient (12, 47, 51). The results of our study group also 
support this notion. Likewise, there are differences in colonisation of Candida 
albicans on OSCC lesion compared to the healthy site but it is still uncertain and 
debatable whether microbial invasion is a causal or secondary event in oral 
premalignant and malignant lesions (48, 51).  
There are several mechanisms by which different microbes may play a role in 
cancer development. It has been proposed that microbes affect mucosal cells 
through the induction of chronic inflammation (62), by interfering, either directly 
or indirectly, with eukaryotic cell cycle and signalling pathways (142), or via the 
metabolism of potentially carcinogenic substances, acetaldehyde (36, 38, 39). 
Several bacteria and Candida strains in the mouth can produce carcinogenic 
acetaldehyde from alcohol which may explain why poor oral hygiene is often 
associated with oral cancer in heavy drinkers and smokers (48, 143). One of the 
molecular pathogenesis of oral cavity cancer is the inactivation of tumour 
suppressor p53 (90). 
Recent research has provided us considerable amounts of information regarding 
the microbial mechanisms purported to cause oral cancer. However, it is still 
debatable whether microbial infections initiate cancer, or is it the preexisting 
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cancer that compromises the host's immunity followed by secondary microbial 
colonization (144). In addition, a debatable question is that, would certain 
bacteria in saliva or on the OSCC lesion be of any estimable value in the diagnosis 
or treatment of oral cancer, respectively (145). Thus, to demonstrate a role for 
microbes in the development of OSCC or OLD, the first step must be to identify 
such organisms on the lesion. This emphasises the importance of the correct 
sampling method and sampling site for the analysis of lesion specific microbes.   
4.4.7 Treatment 
Surgery, radiotherapy, and chemotherapy are three primary approaches to cancer 
treatments and during these treatments the oral cavity goes through radical 
changes (146). Surgical excision of the tumour often results in considerable lack 
of tissue, and pedicled flaps or free tissue transfers of bone, skin and muscle are 
used for reconstruction. Radiotherapy to the primary tumour site and regional 
lymph nodes, as a pre- or postoperative treatment are given to patients with 
aggressive and large tumours and ones at risk for metastases. Radiotherapy 
usually starts as soon as the primary healing of the operation wounds has 
completed (146). The combined chemotherapy with radiotherapy has an 8% 
effect on the 5-year overall survival in head and neck cancer (147).  
For most patients, anticancer therapy, irradiation, chemotherapy, or surgery 
results in permanent damage to their salivary glands and lifelong xerostomia. In 
addition, the increase of keratinised surfaces when skin-lined microvascular flaps 
are used alter the micro-environment of the oral cavity (148). Thus, anticancer 
therapy compromises the defence mechanism of the oral mucosa and is 
accompanied by a proliferation of the mucosal biofilm with an overgrowth of yeast 
and bacteria (144). Lack of saliva and changes in oral surfaces making them more 
susceptible to heavy yeast colonization cause a lifelong high risk for oral 
candidosis for these patients (20). In fact, cancer lesions itself might even increase 
the local and systemic infection risk in oral cancer patients, even before specific 
tumour treatment (144).  
To prevent or treat oral mucositis in patients receiving radiation and/or 
chemotherapy a regular use of oral care protocols consisting of brushing, flossing, 
rinsing, and moisturizing, are important (149). The post-operative antimicrobial 
treatment should be targeted against pathogens which should be identified using 
a reproducible sampling method. Traditional sampling methods, e.g. mouth rinses, 
saliva culture or tongue scrapings, are often impossible to perform due to the 
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xerostomia and changes after surgical treatments and may result in false negative 
results. This is especially problematic, as clinical symptoms may be non-existent 
due to neural damage and to the decrease in blood flow in the irradiated and 
reconstructed tissues (20). The optimal site and method of sampling for oral 





5 AIMS OF THE STUDY 
The objectives of this thesis were to investigate how the method and site of 
microbial sampling affect the discovery of oral microbial flora on OSCC lesions. 
Secondly, to explore the ability of lesion specific oral microbes to produce 
acetaldehyde in OLD and OSCC patients using a quantitative sampling method. 
Furthermore, to investigate the immunohistochemical expression and tissue 
localization of TLR, p53 and NF- B in mucosal biopsies from patients with OLD. 
The specific aims were as follows: 
I. To investigate how the sampling method and site affect the discovery of 
Candida species from the oral cavity in OSCC patients.  
II. To develop a site-specific and easy-to-use sampling method that would 
give representative and quantitative results for samples from the oral 
mucosa. 
III. To explore the lesion specific microbial flora in OLD and OSCC patients 
using a site-specific and quantitative sampling method and to explore the 
ability of these microbes to produce acetaldehyde when exposed to 
clinically relevant levels of ethanol. 
IV. To compare the immunohistochemical expression levels and tissue 
localization of TLR1–10, p53 and NF- B in mucosal biopsies from patients 





6 MATERIALS AND METHODS 
6.1 MATERIALS 
6.1.1 Subjects and study design (I-IV) 
Study I: Eighteen previously untreated patients with primary oral cancer were 
enrolled in the study (Table 3). All patients were hospitalized due to oral cancer 
treatment during 2004–2005 (mean age 60 years, range 42–81, female:male ratio 
7:11). Five non-medicated volunteers of the hospital personnel were included as 
healthy controls (mean age 42 years, range 28–54 years, female:male ratio 2:3). 
For this study, five patients were examined prior to all cancer treatment and 
thirteen patients were examined 2–4 weeks (n = 5) or 8–12 weeks (n = 8) after the 
primary surgical treatment. From the thirteen patients who had undergone 
surgery, two received chemoradiotherapy and eleven received conventionally 
fractionated radiotherapy (mean total dose of 55 Gy; range 20–76 Gy) post-
operatively. The primary sites of the oral cancer were the tongue (n = 6), buccal 
mucosa (n = 1), mandible (n = 6) and maxilla (n = 2). In three cases, metastasis had 
been identified. The general status of the dentition and dental status was recorded 
according to the WHO Diseased Missing Filled (DMF) Index. The oral hygiene 






Table 3. Subjects of the first study. 
 
Study II: From the staff of the Department of Bacteriology and Immunology of 
Helsinki University a total of fourteen non-medicated healthy volunteers with 
good oral health, were enrolled in the study (mean age 36 years, range 27–50, 
female:male ratio 7:7). The subjects were not receiving any systemic or topical 
antimicrobial treatment at the time of sampling or during the previous three 
months. The volunteers were asked not to consume any food for 1 hour prior to 
the sampling. 
Study III and IV: A total of 90 patients, 30 with newly diagnosed primary oral 
squamous cell carcinoma (OSCC), 30 with oral lichenoid disease (OLD) and 30 
healthy controls treated at the Department of Oral and Maxillofacial Surgery, 
Helsinki University Central Hospital or at the Helsinki University Dental Hospital 











Total number 5 5 8 18 5 
    Female:male 1:4 2:3 4:4 7:11 2:3 
Age (years)      
Mean 61 57 62 60 42 
Range    42–81 28–54 
Location of the 
cancer 
    
 
Tongue 1 0 4 5  
Buccal mucosa 1 0 0 1  
Floor of the mouth 1 3 3 7  
    Maxilla 0 1 1 2  
Metastasis 2 1 0 3  
Treatment      
Surgery 0 5 8 13  
Radiotherapy 0 3 8 11  
   Mean dose    54 Gy  
   Dose range    20–76 Gy  
Chemoradiotherapy 0 1 1 2  
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during 2007–2011 were enrolled (Table 4). For the third study, microbial samples 
were collected from all three patient groups and for the fourth study, surgical 
biopsies were collected from OLD and control groups. Patients potentially suitable 
for enrolment were identified from weekly theatre list by the research team 
member and the exclusion criteria were antimicrobial therapy (i.e. antibiotics, 
antifungals, or antiviral agents) within the past seven days and HIV or hepatitis 
virus infection. All study participants were generally well without any systemic 
diseases or immune suppression predisposing them to infection.  
Patient questionnaire. The subjects filled in a modification of the World Health 
Organization Alcohol Use Disorders Identification Test (WHO AUDIT) 
questionnaire including open and closed questions about their drinking and 
smoking habits (150). Approximated daily and weekly amounts of consumed 
alcohol and tobacco were recorded, and the consumption were based on self-
reporting. Patients who smoked regularly were defined as smokers. A member of 
the research team gave the forms to the participants and was available in case of 
any questions.  
Patients with OSCC. Thirty patients with clinically and histopathologically 
diagnosed OSCC were enrolled. The anatomical sites of the cancerous lesions were 
the tongue (n = 9), the gingiva (n = 10), the sulcus (n = 2), the floor of the mouth 
(n = 5), the palate (n = 3), and the tonsil (n = 1). 
Patients with OLD. Thirty patients were enrolled into the study with the clinical 
diagnosis of OLD from which twenty-four cases were histologically confirmed as 
oral lichen planus (OLP; n = 10) or lichenoid reaction or lichenoid lesion (OLR or 
OLL; n = 14). The anatomical sites of the OLD lesions were the tongue (n = 7) and 
the buccal mucosa (n = 17).  
Healthy controls. Thirty generally healthy individuals, which were patients 
referred to the Department of Oral and Maxillofacial Surgery for operative wisdom 
tooth extraction were included as healthy controls. Healthy control patients had 





Table 4. Subjects of the third and fourth study. 
 OSCC OLD Controls 
Total number 30 24 30 
  Female: male 12:18 16:8 19:11 
Age in years (range) 65.6 (39-85) 54 (24-74) 30.4 (19-56) 
Smokers 9 (32%) 4 (19%) 9 (31%) 
    Female: male 2:7 2:2 5:4 
Non-drinkers 6 (21%) 2 (10%) 3 (10%) 
Alcohol consumers 23 (79%) 19 (91%) 26 (90%) 
    Female: male 8:15 15:7 16:11 
Heavy drinkers 5 (17%) 1 (5%) 2 (7%) 
    Female: male 0:5 0:1 2:0 
Non-responders 1 (3%) 3 (13%) 1 (3%) 
Location of the 
lesion 
   
    Tongue 9 7  
    Buccal mucosa 0 17  
    Gingiva 10 0  
    Sulcus 2 0  
    Floor of the mouth 5 0  
    Palate 3 0  






6.2.1 Sampling methods (I, II and III)  
Study I: For culture of yeasts, eighteen oral cancer patients and five control 
subjects were sampled once semi-quantitatively from the labial sulcus, saliva, 
dental plaque, and dorsum of the tongue. All samples were taken non-invasively 
with sterile instruments and cotton swabs and care was taken to perform the 
sampling in a standardized way and to avoid contamination from adjacent areas. 
The precise site of sampling varied a little from patient to patient, depending on 
the dentate status and anatomical circumstances in the mouth due to the 
anatomical changes after surgical treatment. For the labial sulcus sample, each 
sulcus was gently swabbed with single swipes and the saliva sample was collected 
by placing the swab into a moist area in the floor of the mouth for 10 s. The dental 
plaque sample was taken from the labial surface of one lower molar tooth using a 
gingival probe. Samples from the dorsum of the tongue were taken with one gentle 
scrape using a spatula. 
Study II: Two site-specific non-invasive sampling methods for microbiological 
analyses of the healthy oral mucosa were compared. The samples were obtained 
using a filter paper and swab using a standardized procedure as far as possible. 
The filter paper sampling method was developed for this study. Samples from 
adjacent areas on buccal mucosa for each subject were collected consecutively in 
the following order, i.e. swab sample and filter paper imprint sample. For the swab 
sample an area of diameter approximately 13 mm, estimated using a template, 
was rubbed with a dry and sterile swab (Copan Diagnostics, Corona, USA). For the 
filter paper sample, a hydrophilic mixed cellulose ester MF-Millipore Membrane 
filter (GSWP01300; Millipore Inc., MA, USA, pore size 0.22 μm, diameter of 13 mm) 
was placed gently on the buccal mucosa for 30 s, with the glossy side of the filter 
paper placed against the mucosa (Figure 3). The optimal time for the filter paper 







Fig. 3. Schematic illustration of the filter paper. The pore size (0.22 μm) of the 
hydrophilic filter paper allows capillary flow of saliva into the filter paper creating 
a gentle suction and thereby releasing adherent microorganisms without rubbing. 
The filter paper sampling method was developed for the study II.  
  
 
Study III: After clinical assessment, microbial samples for microbiological 
analyses and acetaldehyde measurement were obtained using the filter paper 
sampling method described in the study II. In OSCC and OLD patient groups two 
samples were collected from each patient: one from a representative mucosal 
lesion and another from a clinically healthy contralateral site. Samples from the 
healthy controls were obtained from the buccal mucosa. Sampling methods and 




Table 5. Sampling methods and sites in study I, II and III.  
















Swab Gently  
swipe 
Sulcus X   
 Saliva X   
  Buccal 
mucosa 


















Oral   
mucosa (III) 
 X   
X X 
 
6.2.2 Collection of histopathological samples (IV) 
As part of routine histopathological diagnostics full thickness biopsies including 
epithelial and stromal tissue were collected from the site of active disease process 
of OLD patients. The samples were fixed in 10% buffered formalin and embedded 
in paraffin. The diagnoses of OLP, OLL or OLR were based on the clinical and 
histopathological criteria provided by the World Health Organization (108) and 
clarified by van der Meij (151). Of the 30 patients enrolled into the study with the 
clinical diagnosis of OLD 24 were histopathologically confirmed as OLP (n = 10) 
or OLL/OLR (n = 14). The remaining six samples were diagnosed as 
hyperkeratosis (n = 4), epithelial hyperplasia (n = 1) and morsicatio (n = 1) and 
were excluded from the analyses (Figure 4). The biopsies from healthy control 
patients were taken from the non-inflamed, healthy buccal mucosa at the incision 





Fig. 4. Patients in the study IV. Of the 30 patients enrolled into the study with the 
clinical diagnosis of OLD, 24 were histopathologically confirmed as OLP (n = 10) 
or OLL/OLR (n = 14). The diagnoses were based on the clinical and 
histopathological criteria provided by the World Health Organization and clarified 
by van der Meij (108, 151). 
 
 
6.2.3 Culture (I, II and III) 
For the identification and culture of yeasts and bacteria the microbiological 
samples were immediately taken to the laboratory, Department of Bacteriology 
and Immunology, Haartman Institute, University of Helsinki, and all samples were 
cultured within one hour. 
Study I. For the culture and identification of yeasts the samples were collected into 
sterile tubes containing 0,5ml sterile saline and after vortexing 100μl of the saline 
was plated onto Sabouraud dextrose plates (SP; Sabouraud Dextrose Agar [Lab 
M], Bacto Agar [Difco Laboratories, Basel, Switzerland] supplemented with 
penicillin [100,000 iu/ml] and streptomycin) and incubated at 37°C for 48h. 
Thereafter, colonies were further counted and cultivated on CHROMagar Candida 
medium (CHROMagar) for the identification of Candida species. The Bichro-Dubli 
latex co-agglutination test (Fumouze Diagnostics) was used to differentiate 
between C. albicans and C. dubliniensis and species other than C. albicans and C. 
dubliniensis were identified by API 32C auxanographic strips (bioMérieux) (Figure 
5). Multiple colonies were tested at every identification step.  
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Study II and III. The samples were collected into sterile tubes containing 5ml 
sterile saline and mixed for 30s with five sterile ∅3 mm glass beads. Samples were 
further diluted 10-fold and 100μl of the dilution were cultured on selective and 
nonselective media under aerobic and anaerobic conditions to detect and 
enumerate: 
1. yeasts 
Sabouraud dextrose plates (SP; Sabouraud Dextrose Agar [Lab M], Bacto 
Agar [Difco Laboratories, Basel, Switzerland] supplemented with penicillin 
[100,000 iu/ml] and streptomycin) was used. 
2. total cultivable bacteria 
Fastidious anaerobe agar (FAA; Fastidious Anaerobe Agar; LAB 90 [Lab M, 
Lancashire, UK] supplemented with 5% horse blood) was used. 
3. total aerobic bacteria 
Lysed blood agar (BA; Trypticase soy agar [BBL 211047; BD Diagnostics, 
Franklin Lakes, NJ, USA] and Mueller Hinton agar [BBL 212257; BD 
Diagnostics] supplemented with 5% horse blood) was used. 
4. anaerobic gram-negative bacteria 
Neomycin-vancomycin blood agar (NV; blood agar and neomycin sulfate 
[Sigma N1876; Sigma-Aldrich, St. Louis, MO, USA] supplemented with 
vancomycin [7.5 m/ml], menadion [0.5 mg/ml] and sheep blood 5%) was 
used. 
5. aerobic gram-negative fermentative rods 
Cysteine-, lactose- and electrolyte-deficient agar (CLED; C.L.E.D. medium 
[BBL 212218; BD Diagnostics]) was used. 
FAA and NV plates were incubated under anaerobic conditions at 37°C for seven 
days and BA, CLED and SP plates were incubated at 37°C for two days. For the 
acetaldehyde analyses, both sides of the filter paper were placed onto an FAA plate 
for 30s and plates were evenly streaked and incubated as described above. After 
incubation, the numbers of bacteria and yeasts were enumerated [colony forming 
units (CFU)]. Gram stain was performed on all different colony morphology types 
from NV and CLED agars and the number of gram-negative colonies was 
enumerated. The ratio of aerobic to anaerobic bacteria and the ratio of gram-





Fig. 5. Schematic illustration of the culture and identification of yeasts and bacteria 
in study I, II and III. BA and CLED were incubated in aerobic conditions (O2) and 
FAA and NV plates under anaerobic conditions (O2). For the acetaldehyde (ACH) 
analyses both sides of the filter paper (fp) were placed directly onto an FAA plate 






6.2.4 Acetaldehyde analysis (III) 
Microbial colonies on the FAA plate were carefully scraped and washed off with 
3ml of sterile saline solution and 400μl of the solution was transferred into 
parallel gas chromatograph vials. Then 50μl of phosphate buffered saline 
containing ethanol (final concentration 22 mM) was added, after which the vials 
were sealed immediately, and the samples were incubated for 1h at 37°C. The 
reactions were ended by injecting 50μl of 6M perchloric acid (PCA) through the 
rubber septum of the vial. Control vials in which perchloric acid was added prior 
to ethanol were used to measure background acetaldehyde and ethanol levels. 
Three parallel samples were analysed, and the mean values were used for 
statistical analysis. The formed ACH levels were measured by gas chromatography 
(Perkin Elmer Headspace Sampler HS 40XL, Perkin Elmer Autosystem Gas 
Chromatograph equipped with Ionization Detector FID, Waltham, MA, USA) (152). 
6.2.5 Immunohistochemical staining (IV) 
Sixty tissue sections (30 OLD and 30 control sections) were prepared for the 
histopathological diagnosis and immunohistochemical analyses. Tissue sections, 
4μm in thickness, were prepared from the paraffin embedded samples and 
applied to glass slides followed with deparaffination in xylene and rehydration in 
graded ethanol. The sections were incubated in pepsin for 30min at room 
temperature to expose the antigenic determinants after formalin fixation and 
paraffin embedding. Endogenous peroxidase activity was quenched in the 
sections by incubating in hydrogen peroxidase in methanol.  
TLRs. The optimal primary antibody concentrations for immunohistochemistry 
was selected based on a pilot study. The final IgG concentrations of the polyclonal 
anti-human antibodies used in the study IV are shown in the table 6. Control 
incubations were performed by replacing primary antibodies with protocol 
buffer. Sections from each sample were also stained with periodic acid-Schiff 
(PAS) to determine the presence or absence of candida species. The TLRs were 
visualized using avidin-biotin-peroxidase complex method (catalogue nos., PK-
4001 and PK-4005; Vectastain ABC kit; Vector Laboratories, Peterborough, 
England).  
NF- B and p53. For the immunohistochemical staining with NF- B, the tissue 
sections were buffered in citrate, pH 6 and heated for 10min in microwave oven 
and incubated for 1h in room temperature with an optimally diluted NF- B 
antibody. For the immunohistochemical staining of p53, the tissue sections were 
 43 
 
buffered in Tris-EDTA, pH 9 and heated 15min in microwave oven and incubated 
for 30min RT with an optimally diluted p53 antibody. The concentrations of NF-
κB and p53 IgG antibodies used in this study are shown in the table 6. After the 
primary antibody incubation, the tissue sections were incubated separately with 
Dako REAL™ EnVision™ kit using Dako automated immunostaining instruments. 
The reactions were visualized by Dako REAL™ DAB+ Chromogen also included in 
the kit (catalogue number K5007, Dako Glostrup Denmark). Control incubations 
were performed by replacing primary antibodies with protocol buffer.  
Gingival tissue samples from patients with chronic periodontitis obtained during 
periodontal flap operations were used in the pilot study and in the fourth study as 




Table 6. The optimal IgG concentrations of the polyclonal anti-human antibodies 
used in the study IV. 
Primary 
antibody Type Dilution Catalogue nr. 
TLR1 polyclonal rabbit IgG 1:50 sc-30000* 
TLR2 polyclonal rabbit IgG 1:50 sc-8689* 
TLR2 polyclonal goat IgG 1:50 sc-10739* 
TLR3 polyclonal rabbit IgG 1:50 sc-10740* 
TLR4 polyclonal rabbit IgG 1:50 sc-10741* 
TLR5 polyclonal rabbit IgG 1:50 sc-10742* 
TLR6 polyclonal rabbit IgG 1:50 sc-30001* 
TLR7 polyclonal rabbit IgG 1:40 sc-30004* 
TLR8 polyclonal rabbit IgG 1:50 sc-25467* 
TLR9 polyclonal rabbit IgG 1:40 sc-25468* 
TLR10 polyclonal rabbit IgG 1:40 sc-30198* 
NF-κB polyclonal rabbit IgG 1:150 sc-114* 
p53 monoclonal mouse IgG 1:600 M7001** 
*=Santa Cruz Biotechnology, Santa Cruz, California, USA 
**=Dako Glostrup Denmark 
 
6.2.6 Microscopical analyses (IV) 
The immunohistochemical expression for TLR1-TLR10, p53 and NF- B was 
analysed using a light microscope (Nikon Eclipse 80i). Results were scored semi-
quantitatively and photographed using an attached camera (Nikon DS-Fi1).  All 
samples and staining’s were analysed and scored by four authors (Peter Rusanen, 
Jaana Hagström, Emilia Marttila and Tuula Salo) blinded for each other’s scoring 
and clinical data and discrepancies were settled within the team. The staining 
quantity of the basement membrane (BM) zone and of the cells in the basal, 
intermediate, and superficial layers of the epithelium were scored in a four-point 
scale as follows: 
0 = no staining 
1 = staining of approximately 1-33% of cells or of the BM zone 
2 = staining of 34-66% of cells 
3 = staining of 67-100% of cells 
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6.2.7 Statistical methods 
Data is presented as means (study I – IV), in standard error of mean (  SEM; study 
II – IV) and in standard deviation (study II). The statistical differences were 
analysed by using GraphPad Prism version 5.00 (GraphPad Inc. San Diego, 
California, USA; study II, III and IV). The Mann-Whitney test was used for the 
analysis of the colony morphology types on different agars (study II). The two-
tailed Mann Whitney test and Spearman’s rho (rS) was used for the analyses of 
correlations and the Wilcoxon signed-ranks test was used to compare the 
differences between the different layers of samples (study III and IV). P-values of 
less than 0.05 were considered statistically significant. 
6.2.8 Ethical considerations 
The study protocol was approved by the ethical committee of the Helsinki 
University Central Hospital (study I-IV; study I: ethical permit number 
525/E6/2003 28.01.2004; study II – IV: § 47/2007, 25.4.2007, Dnro 126/E6/07). 





7 RESULTS  
7.1 OPTIMAL SAMPLING SITE IN OSCC PATIENTS (I) 
40% of the control subjects and the pre-operative groups had positive Candida 
growth. However, the colony density was found to be markedly higher in the OSCC 
patient group before the cancer treatment compared to the controls (Figure 6). 
After cancer treatment, the incidence was found to be increased and 69% (9/13) 
of the patients were positive for C. albicans. Of the patients who had undergone 
operations, 75% (6/8) were positive for Candida 8-12 weeks post-operatively 
(Figure 6). In addition to the increase of the incidence of Candida, the colony 
forming units (CFU) also increased after the beginning of the cancer treatment. 
The most sensitive sampling site was found to be the labial sulcus, from which all 
Candida positive cases could be confirmed. However, the number of CFU was 
highest in the dental plaque samples. The samples from the dorsum of the tongue 
was found to be more sensitive than saliva in detecting Candida in the patients and 
in the healthy controls. In detecting the different species of Candida, all sampling 
methods were equally sensitive. 
C. albicans was found to be the predominant species and it was the only yeast 
detected in the control group as well as in the patient groups before and 2-4 weeks 
after the cancer treatment. In the patients at 8-12 weeks after the cancer 
treatment, 50% of the Candida-positive patients, species other than C. albicans 
was identified (Figure 6). C. dubliniensis was not found in any of the patient 
samples. Antifungal prophylaxis, mainly fluconazole 100mg p.o. or 150 mg i.v. 
daily, had been given to 44% of the patients. About half of the patients who 
received antifungal treatment still had positive yeast growth, mainly of species 
other than C. albicans. Of the seven patients with negative yeast growth, four were 
receiving antifungal treatment. Of the patients undergoing radiotherapy, 67% had 
positive yeast growth, although 63% were receiving antifungal treatment. All 
patients receiving chemoradiotherapy had positive yeast growth.  
Oral hygiene and the general status of the dentition of the patients was recorded. 
Of the patients, ten were smokers from which seven had positive yeast growth. A 
hospital dentist had seen all patients preoperatively. Patients had no cavities but 
had a higher number of missing teeth in the post-operative phase of cancer 
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treatment. The oral hygiene of the patients improved during their cancer 
treatment. 
 
Fig. 6. Incidence of Candida species in oral cancer patients at different stages of 
treatment, and in control subjects. In the patients at 8-12 weeks after the cancer 
treatment, 50% of the Candida-positive patients, species other than C. albicans 
was identified. wk: week; post-op.: post-operatively. Modified from Rautemaa et 
al. 2006 (155). 
 
 
7.2 Novel filter paper sampling method (II) 
The filter paper sample detected a higher number of CFU of aerobic and anaerobic 
bacteria compared to the swab. The mean of the total number of morphology types 
per sample recovered on FAA was 17.7 (SD±2.95) using the filter paper and 15.1 
(SD±2.8) using the swab; these values equate to 0.13 (SD±0.02) and 0.10 
(SD±0.02) colony morphology types of bacteria per square mm of oral mucosa, 
respectively. The difference was statistically significant on FAA (P=0.0094). On the 
BA, CLED and NV culture media the difference were not significant. 
The filter paper sample did not significantly differ from the swab in the gram-
positive/gram-negative ratio (median: filter 25.9; swab 62.3) or for the 
aerobic/anaerobic ratio (median: filter 2.3; swab 3.5). The mean of the total 
number of CFUs was 0.4×105 (SD±0.5×105) per filter paper sample and 1.4×105 
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(SD±1.7×105) per swab sample. The difference was statistically significant 
(P=0.0001). Both sampling methods did not differ in their sensitivity in detecting 
yeast colonization; both detected yeast from only one subject. 
7.3 ACH PRODUCTION AND MICROBIAL COLONIZATION IN OLD AND OSCC (III)   
The majority (68%) of the cultures from the patient samples produced mutagenic 
levels of acetaldehyde (>100 mM): 76% of all OSCC lesion samples; 72% of OSCC 
control samples; 61% of OLD lesion samples; 67% of OLD control samples; 60% 
of samples from control patients (P = ns). The mean level of acetaldehyde 
produced by all samples was 158 μM (range 13-1000 μM). The differences 
between patient groups and sampling sites were not statistically significant and 
there were no significant differences in the acetaldehyde production between 
clinically and histologically diagnosed oral lichen planus (OLP) and oral lichenoid 
reaction (OLR).  
As determined by CFU per sample, in OSCC lesions were significantly higher 
numbers of microbes compared with the other patient groups (P < 0.0001; Figure 
7). Likewise, the number of aerobic and anaerobic bacteria (CFU/sample) cultured 
from the OSCC lesion site was significantly higher compared with the other patient 
groups (P < 0.0001; Figure 7). There was no significant difference in the number 
of anaerobic bacteria per sample between lesion and control site of OSCC patients. 
In OLD patients, there was no significant difference in the microbial colonization 
density in lesion or control sites compared with control patients, or between OLD 
patients histologically diagnosed with OLP and OLR. Most bacteria cultured from 
samples from all patient subgroups were gram-positives. In OSCC patients, mean 
4% in lesion site and 3% in control sites were gram-negatives. Likewise, in OLD 
patients, 12% in lesion sites and 8% in control sites were gram-negatives. In 
control patients 8% of the cultured bacteria were gram-negatives. 
The density and frequency of Candida was higher in lesion sites compared to the 
control sites or samples from control patients. In OSCC patients, Candida was 
found from 27% of the lesion and 10% of the control sites and in OLD patients, 
Candida was found in 8% and 4% of the lesion and control sites, respectively. 
Candida was found in 3% of the control patients (Figure 7). Samples cultured from 
lesion sites of OSCC and OLD patients with Candida colonization produced 
significantly more frequently of mutagenic amount of acetaldehyde than cultures 
of patients with no candidal colonization (P = 0.0008). However, there was no 
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correlation between the total amount of cultivable microbes and acetaldehyde 
levels in any patient group or sample site.  
The mean acetaldehyde production by microbes cultured from samples of 
smokers was significantly higher than from non-smoker samples (P = 0.033). In 
addition, microbes isolated from the lesion sites of smoking OSCC and OLD 
patients produced significantly higher amounts of acetaldehyde than microbes 
isolated from mucosal lesions of non-smokers (OSCC and OLD lesions combined) 
(P = 0.0351). However, non-smoker lesions had higher microbial density than 
smoker lesions (CFU/sample). In addition, on the lesion site (but not on control 
sites) of OSCC patients who did not consume any alcohol were significantly higher 
number of microbes compared to patients who consumed alcohol (mean 
1,400,000 and 560,000, respectively; P = 0.00063).  
No correlations between microbial colonisation or acetaldehyde production and 





Fig. 7. Microbial colonisation (CFU/sample) in the different patient groups and 
sites presented as means. Significantly higher numbers of microbes were detected 
in lesions of OSCC patients compared to the control site and other patient groups 
(P < 0.0001). Likewise, the numbers of aerobic and anaerobic bacteria cultured 
from the OSCC lesion site were significantly higher compared to other sites (P < 
0.0001). The proportion of Candida-positive samples of each sample type are 






7.4 TLR, NF-ΚB AND P53 EXPRESSION IN OLD (IV) 
All TLRs, except TLR2, were expressed throughout oral epithelia in both OLD and 
control samples. TLR2 was not detected in the basal layer or the basement 
membrane (BM) zone of the control samples and was seen in only one OLD sample 
in the BM zone. Likewise, TLR3 expression was detected throughout the 
intermediate and superficial layers of the OLD and control samples but in only one 
of the OLD samples in the BM zone. In contrast, the staining intensity of TLR4 was 
significantly stronger in the BM zone compared to the other layers in OLD and 
control samples (Figure 8). 
 
Fig. 8. Staining intensity of TLR4 in basement membrane zone in healthy control 
(red arrow, x40). The staining intensity of TLR4 was significantly stronger in the 
BM zone compared to the other layers in OLD and control samples. Modified from 





The expression of most of the TLRs had a trend of a gradual decrease from the 
superficial layers towards the basal layer. Expression was strongest in the 
superficial layer for all TLRs, except for TLR3 and TLR4 in the control samples, 
and TLR4 and TLR9 in the OLD samples. In general, the expression of several TLRs 
was markedly upregulated in the OLD samples compared to the control samples 
(Figure 9). In the superficial epithelium, the staining intensity for TLR1, TLR3 and 
TLR4 was significantly higher in OLD compared to the control samples (P = 0.01, 
P = 0.002, P = 0.02, respectively; Figure 9). Likewise, the staining intensity for 
TLR1, TLR3, TLR4 and TLR6 was significantly higher in the intermediate layer of 
OLD samples (P = 0.03, P = 0.003, P = 0.03, P = 0.02, respectively). Also, in the basal 
layer, the expression of TLR1, TLR5, TLR6, and TLR7 was increased in the OLD 
group when compared to the control group (P = 0.02, P = 0.02, P = 0.0004 and P = 
0.03, respectively). In the BM zone, the expression of TLR5 was upregulated in 
OLD when compared to control samples (P = 0.03). In contrary, the expression of 
TLR3 and TLR7 in the BM zone was stronger in the control samples compared to 
the OLD samples (P = 0.007 and P = 0.04, respectively). All control samples 
showed a positive staining to all TLRs. The immunohistochemical expression of 




Fig. 9. Mean staining percentage of TLRs in epithelial layers and basement 
membrane (BM) zone. In general, the immunohistochemical expression of several 
TLRs was markedly upregulated in oral lichenoid disease (OLD). *: P < 0.05;             




The expression of p53 increased from the superficial layers towards the basal 
epithelium in both control and OLD samples. Staining for p53 could not be 
detected in the superficial epithelial layers of the control samples, whereas two of 
the OLD cases showed weak staining (1–33% of cells) in this layer. In the control 
group, staining for p53 could be detected only in one sample in the intermediate 
layer and in five samples in the basal layer. The immunohistochemical expression 
for p53 was statistically stronger in basal layer compared to the intermediate 
layer in the control group (P = 0.02). In OLD samples, the staining intensity was 
significantly stronger in the intermediate layer compared to the superficial layer 
(P = 0.002) and in the basal layer compared to the superficial and intermediate 
layers (P = 0.001, P = 0.003, respectively). In general, the staining intensity of p53 
was stronger in the OLD samples compared to the control samples in all layers. 
The difference was statistically significant in the basal and in the intermediate 
layers (P = 0.002 and P = 0.009, respectively). 
The expression of NF-κB decreased from the superficial epithelial layers towards 
the basal layer in both the control and OLD samples. Immunoreactivity for NF-κB 
could be detected in all epithelial layers in both control and OLD samples. In the 
control samples, the staining for NF-κB was significantly stronger in the 
superficial layer compared to the intermediate and the basal layers (P = 0.001, P 
= 0.0005, respectively). In the OLD samples, the expression of the NF-κB in the 
superficial and in the intermediate layers was significantly stronger compared to 
the basal layer (P = 0.002, P = 0.03, respectively). In general, the staining for NF-
κB was more intense in the OLD samples compared to the control samples. The 
NF-κB expression was significantly stronger in the OLD samples compared to the 
control samples in the intermediate layer (P = 0.04).  
The staining intensity of p53 correlated positively with the staining intensity of 
NF-κB and TLR1 in the basal layer of the OLD samples (P = 0.02 and P = 0.02, 
respectively). Accordingly, NF-κB correlated positively with the immunoreactivity 
of TLR2 (P = 0.05). The correlations of p53, NF-κB and TLRs in OLD are shown in 
figure 10. In the intermediate layer of the OLD samples, the staining intensity of 
p53 correlated positively with the immunoreactivity of NF-κB (P = 0.03), TLR1 (P 
= 0.009) and TLR5 (P = 0.03). However, in the superficial layers of the OLD 
samples or in any layers of control samples, no significant correlations were seen 
in the staining intensities of TLR1-10, p53 and NF-κB. There was no significant 
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difference in the staining intensity for TLR1-10, p53 nor NF-κB in patients with 
OLP and patients with OLR or OLL in any parts of the epithelium. 
 
Fig. 10. The statistically significant differences in the immunostaining of TLR1-10, 
p53 and NF-κB in oral lichenoid disease (OLD) and control samples. P-values of 
less than 0.05 were considered statistically significant. Correlations between 
TLRs, p53 and NF-κB were found only in OLD samples. BM zone: basement 
membrane zone. 
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This thesis showed that the frequency and density of Candida colonization was 
higher in OLD patients and OSCC patients undergoing cancer therapy compared 
to the healthy controls. Also, a shift from C. albicans to other Candida species in 
OSCC patients was seen, which is in accordance with previous studies (24, 157). 
These findings are likely to be a result of an altered host responses, cancer 
treatment and the use of fluconazole in OSCC patients. Although all Candida 
species cause a clinically similar mucositis, there are significant differences in the 
invasiveness and antifungal susceptibilities among species. The increase of the 
prevalence of non-albicans Candida species innately resistant to standard 
fluconazole treatment has significant antimicrobial stewardship implications, 
especially in high-risk patients. The use of non-azole treatment should be 
considered first line in order to avoid selection of these more difficult to treat 
species. 
Most oral microbial samples produced mutagenic levels of acetaldehyde. 
Especially, samples cultured from OSCC and OLD patients with Candida 
colonization produced significantly more frequently of mutagenic amount of 
acetaldehyde than cultures of patients with no candidal colonization. This is in line 
with studies of other that have shown that Candida albicans can produce 
significant amounts of acetaldehyde (45, 158).  
In our study a significantly higher number of aerobic and anaerobic bacteria were 
cultured from OSCC lesion sites compared to other patient groups. Also, in OLD 
lesion samples a higher proportion of gram-negative anaerobic bacteria were 
detected compared to other sample types. In addition, the Candida colonization 
was higher in lesions compared to the control sites and to samples from control 
patients. This in in accordance with the study of Nagy et al (51). A major factor for 
these findings would seem to be the irregularity of the lesion surface providing 
stagnant niches allowing oral commensals to become pathogenic when their 
balance is disrupted. However, acetaldehyde levels produced by the microbes 
cultured from the OLD or OSCC lesion site did not differ from the other subgroups. 
In addition, there was no correlation between acetaldehyde levels and the total 
amount of cultivable microbes in any patient group or sample site. Also, Candida 
spp. was not detected in all samples producing high amounts of acetaldehyde. This 
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indicates that the composition rather than the number of microbes is a significant 
factor that influences the production of carcinogenic level of acetaldehyde.  
Our results supports the findings of other that the total amount of microbes 
isolated from smoking patients were higher compared to the non-smoking 
patients (42, 45, 159). Interestingly, the microbes isolated from the lesion site of 
smoking OSCC and OLD patients produced significantly higher amounts of 
acetaldehyde despite of a significantly lower microbial density compared to the 
lesion site of non-smoking patients. Poor oral hygiene and smoking influences 
immune response, and the healing capacity of the periodontium and oral mucosa 
leading to the changes of the microbial composition (160). It might be that among 
smoking patients the higher acetaldehyde production of microbes in the lesion 
site is rather due to the selection of more acetaldehyde producing microbes than 
the higher number of microbes on the lesion site. It has been shown that 
acetaldehyde is toxic when added to at high concentrations to cell cultures (161, 
162). Thus, the selection of acetaldehyde producing microbes may be due to the 
constant exposure of tobacco smoke that contains acetaldehyde which in turn 
favours microbes that are more tolerant to the acetaldehyde. Also, in the presence 
of alcohol, the acetaldehyde production is increased that might amplify the 
selection of acetaldehyde producing microbes.  
Recent studies of the increased acetaldehyde amount among smokers and alcohol 
consumers are based mainly on uncultured saliva or blood samples (36, 42, 43, 
45). This approach does not give site specific results of the lesion specific microbes 
and its acetaldehyde production. Also, oral swabs for culture is a commonly used 
sampling method but it gives semiquantitative results at the best. In our study the 
measurement protocol for microbial acetaldehyde production was based on 
standardized sample size rather than the number of microbes. Our findings 
underline the importance of using an appropriate lesion specific and quantitative 
sampling method, in addition to performing accurate microbiological diagnostics, 
in these patients. 
In this thesis, the staining intensity of several TLRs was markedly stronger 
throughout the epithelium of OLD compared to the control samples. In addition, 
both OLD and control samples had a trend of a gradual decrease in most of the 
TLRs from the superficial layers towards the basal layer. In epithelium, the 
staining intensity of TLR1, TLR3, TLR4, TLR5, TLR6 and TLR7 were significantly 
higher in OLD compared to healthy controls. Literature on the participation of 
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TLRs in the pathogenesis of OLD is relatively scarce. However, significant increase 
of TLR1, TLR2, TLR4, TLR7, TLR8 and TLR9 has also previously been found in OLP 
compared to healthy controls (114, 117-119, 163). The differences between these 
findings may be due to the differences in the antibodies and the methodology 
used. In addition, different scoring has been used. In this thesis the basement 
membrane zone was recorded separately.  
Lipopolysaccharides (LPS) of gram-negative bacteria and mannan of Candida are 
recognized by TLR4. Thus, the higher immunostaining of TLR4 in superficial and 
intermediate layers of OLD samples might be related to our microbiological 
findings where OLD samples showed a higher Candida colonisation and a higher 
proportion of Gram-negative anaerobic bacteria compared to other sample types. 
When comparing the different layers in OLD and in healthy controls, our results 
revealed a strongest immunostaining of TLR4 in the basement membrane zone 
compared to the epithelium. In addition, the immunostaining of TLR4 in the 
basement membrane zone was stronger in healthy controls compared to OLD 
even though, the difference was not statistically significant. According to the study 
of Zhang et al. (126) the TLR4-stimulated oral keratinocytes inhibited the 
proliferation of OLP CD4+ T-cells and OLP CD8+ T-cells, and simultaneously 
prompted their apoptosis. It might be that TLR4 especially in the basement 
membrane zone play role in the pathogenesis of OLD.  
In OSCC patients, according to our yet unpublished data, the immunostaining of 
TLR4 was significantly lower compared to the same of the healthy controls in the 
basement membrane zone. However, in the epithelium were no significant 
differences in the staining intensity of any TLRs between OSCC and healthy 
controls. In OSCC patients the immunostaining of TLR1-10 were analysed from the 
healthy appearing mucosa near the cancer. Interestingly, according to our yet 
unpublished data, there was a statistically significant association between TLR4 
staining intensity in the basement membrane zone and Candida colonisation in 
OSCC patients. In addition, there was an association between TLR4 
immunostaining in basal layers and acetaldehyde production in OSCC patients. 
According to the meta-analysis of Hao et al. 2018 the elevated expression of TLR4 
in cancer patients is associated with poor overall survival and shorter disease-free 
survival (68). In addition, high TLR4 expression and poor survival rate in OSCC 
patients has been reported (164). On the other hand, in several cancers 
(hepatocellular carcinoma, breast cancer, colorectal cancer and lung cancer) the 
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downregulation of TLR4 has reported to inhibit the tumour growth and 
suppresses the metastasis of carcinoma (165-168). Our results indicate that the 
elevated TLR4 immunostaining in OSCC patients is due to the increased number 
of acetaldehyde producing microbes including Candida spp., which have been 
shown to be heavy acetaldehyde producers  (169). It is still uncertain and 
debatable whether microbial invasion is a causal or secondary event in oral 
premalignant and malignant lesions (48, 51). However, our results indicate that 
acetaldehyde and Candida colonisation have an impact on TLR4 expression that 
may play a role in OSCC pathogenesis. 
In this thesis, the staining for NF-κB was more intense in the OLD samples 
compared to the control samples, especially in the intermediate layer. This is in 
line with the study of Ge et al. (163).  Likewise, consistent to previous studies, the 
staining intensity of p53 in the intermediate and basal cell layers was significantly 
stronger in OLD samples compared to the healthy controls (170, 171). According 
to our results, there was a positive correlation between p53, TLR5 and NF-κB in 
the intermediate layer of OLD samples even though, the immunostaining of TLR5 
in the epithelium did not show significant differences between OLD and healthy 
controls. However, the staining intensity of TLR5 was significantly higher in the 
basement membrane zone of the OLD samples. This may be due to a 
polymorphism and a change in the function of TLR5 that induce the expression of 
p53. The data of the study of Rutkowski et al. (172) indicated that TLR5 signalling 
is sufficient to drive systemic tumour-promoting inflammation due to the 
polymorphism of TLR5. The only known natural ligand for TLR5, flagellin, is 
exclusively of bacterial origin. However, we did not find any correlations between 
the microbial samples and the immunostaining of TLRs.  
In addition to the hitherto known infection sources, plaque, caries and chronic 
inflammatory periodontal disease lesions, our findings supports the studies of 
others that the OSCC and OLD lesion itself may increase the local and systemic 
infection risk and may increase risk of the malignant transformation of OLD 
lesions (62, 109, 135). Oral lichen planus is a systemic disease and even the 
healthy appearing mucosa is diseased, and the malignant transformation is not 
restricted to the site of the lesion (104). It would be of interest to conduct a 
longitudinal study using a site-specific and quantitative sampling method to 
investigate the changes in the microbial flora and its acetaldehyde production on 
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OLD lesions compared to the healthy appearing mucosa whether a connection 
could be found possibly leading to the malignant transformation of OLD.   
8.1 METHODOLOGICAL CONSIDERATIONS 
Microbiological analyses 
In this thesis, the microbes were analyzed using culture-based techniques and 
microbial colonies were classified as Gram-positive or -negative and as aerobic or 
strictly anaerobic. It is well known that culture-based methods have a number of 
limitations and may lack sensitivity compared to molecular methods. This is 
particularly an issue regarding fastidious anaerobic bacteria (173). It has been 
estimated that up to half of oral bacteria are not culturable using standard 
techniques and that gram-negative species are particularly underestimated 
compared to the estimates obtained by qPCR (5, 174). The identification of 
bacterial and yeast isolates by matrix-assisted laser desorption/ionization-time of 
flight (MALDI-TOF) mass spectrometry would also have been more accurate. 
However, the identification by MALDI-TOF mass spectrometry is usually 
performed on microbial biomass extracted from a non-selective culture medium 
which is also prone to biases. In addition, the MALDI-TOF mass spectrometry has 
been in a regular use only recently. However, when delays from sampling to 
plating are minimized like in this study setting, microbial culture is otherwise a 
robust method and a useful diagnostic tool for the detection and identification of 
viable organisms, including many known pathogenic species (173). 
The limitation to the study I is a relatively small number of samples and the lack 
of statistical analyses. However, the results of our study showed that the site of 
sampling for oral yeast cultivation is crucial for correct diagnosis in patients in 
whom surgical operations may have deformed the anatomy of the oral cavity. 
Dental plaque on tooth surface was found to have the highest density of Candida 
colonization of all sites sampled. Thus, it was found to be the most significant 
source of Candida, which emphasizes the role of dental care protocols in these 
patients. However, there is a risk of overdiagnosis and treatment when sampling 
dental plaque from tooth surfaces, as the amount of yeast cultured is used for 
treatment decisions in these patients. Sampling dental surfaces may lead also to 
false negative results if the sampling has performed after a dental care protocol, 
as we noted in our study. In addition, due to the cancer treatment the patient might 
be edentulous. The post-operative antimicrobial treatment should be targeted 
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against pathogens which should be identified using a reproducible sampling 
method.  
In the past decade comprehensive understanding of the oral microbial diversity 
has resulted from improvement in the techniques used in identification of oral 
microbes. Despite of the improvement of these techniques only little attention has 
been given to the first steps in diagnostics i.e. sampling methods. Comparison of 
the findings of various clinical studies is difficult due to the different 
methodologies used. An ideal sampling method that would give representative 
microbial results from site of the active disease process should be minimally 
invasive, site specific, repeatable and quantitative.  A sterile swab is the most 
commonly used method for sampling a mucosal lesion. However, it is influenced 
by a number of variables, such as the area sampled, the force applied to the 
mucosa, and retention of the sample in the swab matrix during plating. In studies 
II and III, these variables are controlled by using a filter paper for sampling. The 
type of filter paper was selected mainly based on its pore size allowing capillary 
flow of saliva into the hydrophilic filter paper creating a gentle suction and 
thereby releasing adherent microorganisms without rubbing but not sucking the 
microbes into the the matrix of the filter paper. In addition, the sample area of the 
filter paper is constant which allows quantitative reporting. Although the type of 
the filter paper was selected not to interfere with PCR, this was not tested in the 
current study and remains to be tested and validated in future work. 
There are some limitations to the study III. The sample size in different sub groups 
in respect of drinking and smoking habits was too small for statistical comparison. 
Moreover, the ACH analyses were done using microbial growth on FAA plates 
which had been plated using filter papers after they had been washed in a sterile 
saline used for the microbial analysis. It is likely that some microbes became 
washed off more than others potentially affecting the ACH analysis. However, all 
samples were analysed in a similar manner and we found clear differences 
between different patient groups and between lesion and healthy appearing 
mucosa of the same patient.  
 
Immunohistochemical staining 
We acknowledge some limitations in this thesis, such as the difference in age 
between the OLD patients and healthy controls. This could partly be attributed to 
the fact that OLD is more common in the adult population, whereas the control 
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samples taken during the surgical removal of third molars is mainly performed in 
young adults. However, it is unlikely that the age gap would have a major impact 
on the findings because, in contrast to adaptive immune responses, the innate 
responses are not generally significantly affected by aging (175). In fact, in this 
thesis, we did not find any age-related correlations with the immunostaining of 
any TLRs.  
The main limitation of the study IV is that only immunohistochemical (IHC) 
staining was used to compare the level of expression of TLRs, NF-kB and p53 
between the OLD and healthy control samples due to limited amount of tissue 
available. IHC staining is an excellent detection technique for visualizing the 
distribution and localization of biomarkers and differentially expressed antigens 
in different parts of tissue levels. IHC staining also gives an indication of the 
amount of the given antigen and it preserves the histologic architecture which 
enables the pathologist to confirm that the positive cells are the cells in question. 
However, its major disadvantage is that it cannot determine if the observed 
biomarkers are active and functional in the tissue. Moreover, by IHC staining, it 
cannot be distinguished whether the p53 is a wild-type or in an inactive form. To 
determine the aetiology of OLD, additional techniques, such as measuring mRNA 
levels by qPCR, should be used to investigate the factors leading to T-cell 
accumulation and the changes in chemokine, chemokine receptor and adhesion 
molecule expression. However, qPCR does not provide site specific information. 
The validity of immunohistochemistry in diagnostic pathology depends on the 
quality of the immunostains and there is a high degree of variability in the way 
tissues are initially prepared. These variations include tissue fixation and 
processing, unmasking of epitopes, and sensitivity of the detection system (176). 
Although we do not have exact information about how the specimen were 
handled, all the biopsies were taken in the hospital or in the university clinic and 
the fixation and processing were carried out by a fixed routine. The optimal 
primary antibody concentrations for immunohistochemistry was selected based 
on our pilot experiments.   
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9 SUMMARY AND CONCLUSIONS 
The results of this thesis have led to the following conclusions: 
I. In oral cancer patients the optimal sampling method and site need careful 
attention, in whom surgical operations may have deformed the anatomy of the 
oral cavity. In this limited patient population, the optimal sampling site for 
Candida was found to be the labial sulcus. We found that Candida colonisation 
was higher in OSCC patients compared to the controls even before the cancer 
treatment. After cancer treatment, the incidence was found to be increased and 
a shift from C. albicans into other Candida species was found. 
II. The novel filter paper sampling method was found to be an ideal technique for 
obtaining quantitative data from defined areas of the oral mucosa. The method 
is easy to perform in a routine setting.   
III. Based on results of filter paper sampling method we found that the bacterial 
composition on OSCC and OLD lesions differed from control site and healthy 
controls. Most of the cultures from the patient samples produced mutagenic 
levels of acetaldehyde. The Candida colonization was higher in OSCC and OLD 
lesions and patients with Candida colonization produced significantly more 
frequently of mutagenic amount of acetaldehyde. However, there was no 
correlation between acetaldehyde levels and the total amount of cultivable 
microbes. Our results indicate that the composition rather than the number of 
microbes is a significant factor that influences the production of carcinogenic 
level of acetaldehyde. This underlines the importance of using a site-specific 
sampling method that gives quantitative results for microbial analysis. 
IV. We were able to map all TLRs, p53 and NF-κB, and their co-localization in the 
epithelium and BM-zone. The increased immunostaining of several TLRs in OLD 
compared to healthy controls indicate an important role in this mucocutaneous 
oral disease. To the best of our knowledge, this thesis is the first to study all TLRs 
in the basement membrane zone. According to our findings, it is likely that 
staining of several TLRs in the basement membrane zone is due to the presence 
of soluble TLRs fragments produced by the basal cells. The role of soluble TLR 
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